Cancer Research and Treatment

Original Articles

Hematologic malignancy

Clinical Impact of Microbiome Characteristics in Treatment-Naïve Extranodal NK/T-Cell Lymphoma Patients: Sang Eun Yoon, Woorim Kang, Junhun Cho, Mauricio Chalita, Je Hee Lee, Dong-Wook Hyun, Hyun Kim, Seok Jin Kim, Won Seog Kim; Cancer Res Treat. 2025;57(2):597-611. Published online August 16, 2024; DOI: https://doi.org/10.4143/crt.2024.675

Abstract PDF Supplementary Material PubReader ePub: Purpose
Extranodal natural killer/T-cell lymphoma (ENKTL) predominantly manifests in East Asia and Latin America. Despite shared intrinsic factors, such as ethnic and genetic backgrounds, the progression of ENKTL can be influenced by extrinsic factors related to changing lifestyle patterns.
Materials and Methods
This study collected stool samples from newly diagnosed (ND)–ENKTL patients (n=40) and conducted whole genome shotgun sequencing.
Results
ND-ENKTL revealed reduced alpha diversity in ND-ENKTL compared to healthy controls (HCs) (p=0.008), with Enterobacteriaceae abundance significantly contributing to the beta diversity difference between ENKTL and HCs (p < 0.001). Functional analysis indicated upregulated aerobic metabolism and degradation of aromatic compounds in ND-ENKTL. Enterobacteriaceae were associated not only with clinical data explaining disease status (serum C-reactive protein, stage, prognosis index of natural killer cell lymphoma [PINK], and PINK-E) but also with clinical outcomes (early relapse and short progression-free survival). The relative abundance of Enterobacteriaceae at the family level was similar between ENKTL and diffuse large B-cell lymphoma (DLBCL) (p=0.140). However, the ENKTL exhibited a higher abundance of Escherichia, in contrast to the prevalence of Enterobacter and Citrobacter in DLBCL. Linear regression analysis demonstrated a significant association between Escherichia abundance and programmed cell death-ligand-1 (PD-L1) levels in tissue samples (p=0.025), whereas no correlation with PD-L1 was observed for Enterobacteriaceae at the family level (p=0.571).
Conclusion
ND-ENKTL exhibited an abundance of Enterobacteriaceae and a dominant presence of Escherichia. These microbial characteristics correlated with disease status, treatment outcomes, and PD-L1 expression, suggesting the potential of the ENKTL microbiome as a biomarker and cause of lymphomagenesis, which warrants further exploration.

1,300 View
113 Download

Nivolumab in Relapsed or Refractory Primary Central Nervous System Lymphoma: Multicenter, Retrospective Study: Jun Ho Yi, Seok Jin Kim, Sang-A Kim, Jongheon Jung, Dok Hyun Yoon; Cancer Res Treat. 2025;57(2):590-596. Published online August 16, 2024; DOI: https://doi.org/10.4143/crt.2024.531

Abstract PDF PubReader ePub: Purpose
Given that 40%-50% of primary central nervous system lymphoma (PCNSL) tissues exhibit aberrancy on 9p24.1, immune checkpoint inhibitors (ICI) may work for the disease.
Materials and Methods
To define the role of ICIs in PCNSL, we carried out a nationwide retrospect analysis for 22 patients who had been treated with nivolumab monotherapy for relapsed or refractory PCNSL.
Results
The median age at diagnosis was 66, and male: female ratio was 1:1. Patients received nivolumab after a median of 3 lines (range, 2 to 6) of therapy and at the median age of 67 years (range, 37 to 82 years). Eleven patients (50%) were refractory to the last treatment prior to nivolumab. With a median follow-up duration of 22.3 months (95% confidence interval [CI], 13.1 to 31.5), nine patients (41%) had an objective response (6 complete responses, 3 partial responses), and the median duration of response was 20.9 months (95% CI, 1.7 to 40.0). The median progression-free survival and overall survival were 2.1 months (95% CI, 0.2 to 4.0) and 18.9 months (95% CI, 5.0 to 32.8), respectively. Nivolumab was generally well-tolerated as no patients required dose reduction and only two patients required delay of treatment.
Conclusion
Our study suggests that nivolumab can be a reasonable option with the durable response for RR PCNSL.

1,296 View
127 Download

Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study: Yoon Seok Choi, Joonho Shim, Ka-Won Kang, Sang Eun Yoon, Jun Sik Hong, Sung Nam Lim, Ho-Young Yhim, Jung Hye Kwon, Gyeong-Won Lee, Deok-Hwan Yang, Sung Yong Oh, Ho-Jin Shin, Hyeon-Seok Eom, Dok Hyun Yoon, Hong Ghi Lee, Seong Hyun Jeong, Won Seog Kim, Seok Jin Kim; Cancer Res Treat. 2025;57(1):267-279. Published online July 16, 2024; DOI: https://doi.org/10.4143/crt.2024.479

Abstract PDF Supplementary Material PubReader ePub: Purpose
This multicenter, open-label, phase II trial evaluated the efficacy and safety of bortezomib combined with dexamethasone for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL) in previously treated patients across 14 institutions in South Korea.
Materials and Methods
Between September 2017 and July 2020, 29 patients with histologically confirmed CTCL received treatment, consisting of eight 4-week cycles of induction therapy followed by maintenance therapy, contingent upon response, for up to one year. The primary endpoint was the proportion of patients achieving an objective global response.
Results
Thirteen of the 29 patients (44.8%) achieved an objective global response, including two complete responses. The median progression-free survival (PFS) was 5.8 months, with responders showing a median PFS of 14.0 months. Treatment-emergent adverse events were generally mild, with a low incidence of peripheral neuropathy and hematologic toxicities. Despite the trend toward shorter PFS in patients with higher mutation burdens, genomic profiling before and after treatment showed no significant emergence of new mutations indicative of disease progression.
Conclusion
This study supports the use of bortezomib and dexamethasone as a viable and safe treatment option for previously treated CTCL, demonstrating substantial efficacy and manageability in adverse effects. Further research with a larger cohort is suggested to validate these findings and explore the prognostic value of mutation profiles.

2,175 View
160 Download

Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma: Sang Eun Yoon, Seung-Ho Shin, Dae Keun Nam, Junhun Cho, Won Seog Kim, Seok Jin Kim; Cancer Res Treat. 2024;56(3):920-935. Published online January 16, 2024; DOI: https://doi.org/10.4143/crt.2023.869

Abstract PDF Supplementary Material PubReader ePub

Purpose
The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy is not clear.
Materials and Methods
We sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes.
Results
Forty samples from patients receiving rituximab-containing immunochemotherapy were analyzed. Baseline sequencing detected mutations in all cases, with the major detected mutations being KMT2C (50%), CREBBP (45%), and KMT2D (45%). The concentration of ctDNA and tumor mutation burden showed a significant association with survival outcome. In particular, the presence of mutations in CREBBP and TP53 showed poor prognosis compared with patients without them. Longitudinal analysis of ctDNA using serially collected plasma samples showed an association between persistence or reappearance of ctDNA mutations and disease relapse or progression.
Conclusion
Analysis of ctDNA mutations in plasma at diagnosis might help predict outcome of disease, while analysis during follow-up may help to monitor disease status of patients with advanced FL. However, the feasibility of ctDNA measurement must be improved in order for it to become an appropriate and clinically relevant test in FL patients.

Citations

Citations to this article as recorded by

Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma
Seok Jin Kim, Jin Ju Kim, Mi Ri Park, Bon Park, Kyung Ju Ryu, Sang Eun Yoon, Won Seog Kim, Saeam Shin, Seung-Tae Lee
Annals of Laboratory Medicine.2025; 45(1): 90. CrossRef
Circulating tumor DNA in lymphoma: technologies and applications
Lina Fu, Xuerong Zhou, Xiaoyu Zhang, Xuhua Li, Fan Zhang, Hongcang Gu, Xiaoxue Wang
Journal of Hematology & Oncology.2025;[Epub] CrossRef
Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future
Jun-Ying Li, Li-Ping Zuo, Jian Xu, Chun-Yan Sun
Blood Reviews.2024; 68: 101237. CrossRef
Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review
Marie Hairing Enemark, Jonas Klejs Hemmingsen, Maja Lund Jensen, Robert Kridel, Maja Ludvigsen
International Journal of Molecular Sciences.2024; 25(20): 11179. CrossRef

3,591 View
174 Download
3 Web of Science
4 Crossref

Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea: Ji Yun Lee, Ji Hyun Kwon, Joon Young Hur, Jun Ho Yi, Ji Hyun Lee, Hyungwoo Cho, Young Rok Do, Jae-Cheol Jo, Hye Jin Kang, Yougil Koh, Won Sik Lee, Sung Nam Lim, Sang Eun Yoon, Seok Jin Kim, Jeong-Ok Lee; Cancer Res Treat. 2024;56(2):681-687. Published online November 10, 2023; DOI: https://doi.org/10.4143/crt.2023.1042

Abstract PDF PubReader ePub

Purpose
Programmed death-1 blockade with pembrolizumab has shown promising activity in relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma (NKTCL), but studies are limited, with small patient numbers.
Materials and Methods
Thirteen institutes involved with the Consortium for Improving Survival of Lymphoma, a Korean lymphoma study group, collected the clinical data of 59 patients treated with pembrolizumab as salvage therapy between 2016 and 2022.
Results
The median age of the patients was 60 years (range, 22 to 87 years), and 76.3% had advanced Ann Abor stage disease. Pembrolizumab was given to 35.6%, 40.7%, and 23.7% of the patients as second-, third-, and fourth- or higher-line chemotherapy, respectively. The overall response rate was 40.7%, with 28.8% having complete response. The estimated 2-year progression-free survival (PFS) and overall survival rates for all patients were 21.5% and 28.7%, respectively; for responders, the rates were 53.0% and 60.7%, respectively. Although not statistically significant, Eastern Cooperative Oncology Group performance status ≥ 2 (hazard ratio [HR], 1.91; 95% confidence interval [95% CI], 0.93 to 3.94; p=0.078) and stage III or IV disease (HR, 2.59; 95% CI, 0.96 to 6.96; p=0.060) were associated with a trend toward shorter PFS in multivariate analysis. Grade 3 or 4 adverse events (AEs) were noted in 12 patients (20.3%); neutropenia (10.2%), fatigue (6.8%), and pneumonitis (5.1%) were most common AEs.
Conclusion
In conclusion, while pembrolizumab had a modest effect on patients with R/R NKTCL, it may be a useful salvage therapy for patients with localized disease and good performance status.

Citations

Citations to this article as recorded by

An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma
Yingfang Feng, Xia Liu, Jingwei Yu, Zheng Song, Lanfang Li, Lihua Qiu, Shiyong Zhou, Zhengzi Qian, Xianhuo Wang, Huilai Zhang
Expert Opinion on Biological Therapy.2025; 25(1): 9. CrossRef
Pembrolizumab

Reactions Weekly.2024; 2025(1): 390. CrossRef

4,183 View
223 Download
1 Web of Science
2 Crossref

Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis: Jinchul Kim, Jinhyun Cho, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim; Cancer Res Treat. 2023;55(3):1031-1047. Published online March 13, 2023; DOI: https://doi.org/10.4143/crt.2022.1658

Abstract PDF Supplementary Material PubReader ePub

Purpose
We intend to evaluate the efficacy of salvage treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) through meta-analysis.
Materials and Methods
R/R DLBCL trials were divided into two groups based on eligibility for autologous stem-cell transplantation (ASCT), and meta-analysis of each group was performed. Random effects models were used to estimate the 1-year progression-free survival (PFS) rate, and chimeric antigen receptor (CAR) T-cell therapy was used as reference treatment.
Results
Twenty-six ASCT-eligible cohorts from 17 studies comprising 2,924 patients and 59 ASCT-ineligible cohorts from 53 studies comprising 3,617 patients were included in the pooled analysis. In the ASCT-eligible group, the pooled 1-year PFS rate was 0.40 (95% confidence interval [CI], 0.15 to 0.65) for the CAR T-cell group and 0.34 (95% CI, 0.30 to 0.37) for the group with chemotherapy followed by ASCT intention. The two treatments were not significantly different in meta-regression analysis. In the ASCT-ineligible group, the pooled 1-year PFS was 0.40 (95% CI, 0.35 to 0.46) for CAR T-cell, and the highest primary outcome was 0.47 (95% CI, 0.37 to 0.57) for the tafasitamab group. CAR T-cell therapy showed significantly better outcomes than chemotherapy and therapies based on ibrutinib, lenalidomide, and selinexor. However, loncastuximab, polatuzumab plus bendamustine and rituximab, and the tafasitamab group showed no different efficacy than CAR T-cell therapy after adjusting for median number of previous lines of treatment.
Conclusion
Although several regimens were crudely grouped for classification, CAR T-cell therapy did not outperform chemotherapy followed by ASCT in the second-line setting or several recently developed agents in the ASCT-ineligible setting.

Citations

Citations to this article as recorded by

Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma
Loretta J. Nastoupil, Clark R. Andersen, Amy Ayers, Yucai Wang, Thomas M. Habermann, Dai Chihara, Brad S. Kahl, Brian K. Link, Jean L. Koff, Jonathon B. Cohen, Peter Martin, Izidore S. Lossos, Michele Stanchina, Sara Haddadi, Carla Casulo, Sabarish Ayyapp
Clinical Lymphoma Myeloma and Leukemia.2025; 25(4): e183. CrossRef
Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis
Hanzala Ahmed Farooqi, Muhammad Saffi Ullah, Ahmed Raza, Zain Sadiq, Wardah Ali Shaikh, Rahmah Muhammad, Muhammad Shoaib Hussain
Critical Reviews in Oncology/Hematology.2025; 207: 104611. CrossRef
Efficacy and Safety of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Patients with Non-Hodgkin Lymphoma
Abdur Jamil, Zaheer Qureshi, Rimsha Siddique, Faryal Altaf, Hamzah Akram, Rohma Jamil, Shehroz Aslam, Insija I. Selene
American Journal of Clinical Oncology.2025; 48(5): 262. CrossRef
Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
Ya Hwee Tan, Dok Hyun Yoon, Andrew J. Davies, Christian Buske, Yang Liang Boo, Nagavalli Somasundaram, Francesca Lim, Shin Yeu Ong, Anand Jeyasekharan, Koji Izutsu, Won Seog Kim, Jason Yongsheng Chan
Discover Oncology.2025;[Epub] CrossRef
Luteolin inhibits diffuse large B-cell lymphoma cell growth through the JAK2/STAT3 signaling pathway
Xin-Zhuo Zhan, Yi-Wen Bo, Yu Zhang, Hai-Dong Zhang, Zhi-Hao Shang, Hui Yu, Xiao-Li Chen, Xiang-Tu Kong, Wan-Zhou Zhao, Timo Teimonen, Tao Liu, Meng-Yi Lu, Ye Yang, Shan-Liang Sun, Hai-Wen Ni
Frontiers in Pharmacology.2025;[Epub] CrossRef
Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol
Mohammadreza Eslami, Mahdi Mehrabi, Mehrdad Payandeh, Fakhredin Saba, Chen Li
PLOS ONE.2024; 19(8): e0308247. CrossRef
Clinical scoring systems, molecular subtypes and baseline [18F]FDG PET/CT image analysis for prognosis of diffuse large B-cell lymphoma
Zhuxu Sun, Tianshuo Yang, Chongyang Ding, Yuye Shi, Luyi Cheng, Qingshen Jia, Weijing Tao
Cancer Imaging.2024;[Epub] CrossRef
Targeting CD22 for B-cell hematologic malignancies
Jia Xu, Wenjing Luo, Chenggong Li, Heng Mei
Experimental Hematology & Oncology.2023;[Epub] CrossRef

8,341 View
680 Download
8 Web of Science
8 Crossref

Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404): Hyungwoo Cho, Dok Hyun Yoon, Dong-Yeop Shin, Youngil Koh, Sung-Soo Yoon, Seok Jin Kim, Young Rok Do, Gyeong-Won Lee, Jae-Yong Kwak, Yong Park, Min Kyoung Kim, Hye Jin Kang, Jun Ho Yi, Kwai Han Yoo, Won Sik Lee, Byeong Bae Park, Jae Cheol Jo, Hyeon-Seok Eom, Hyo Jung Kim, Seong Hyun Jeong, Young-Woong Won, Byeong Seok Sohn, Ji-Hyun Kwon, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2023;55(2):684-692. Published online January 2, 2023; DOI: https://doi.org/10.4143/crt.2022.1434

Abstract PDF Supplementary Material PubReader ePub

Purpose
We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients.
Materials and Methods
Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. All patients were pathologically diagnosed with PTCL.
Results
A total of 191 patients with PTCL were enrolled in this prospective registry study. PTCL, not otherwise specified (PTCL-NOS) was the most common pathologic subtype (n=80, 41.9%), followed by angioimmunoblastic T-cell lymphoma (AITL) (n=60, 31.4%). With a median follow-up duration of 3.9 years, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 39.5% and 60.4%, respectively. The role of upfront ASCT was evaluated in patients who were considered transplant-eligible (n=59). ASCT was performed as an upfront consolidative treatment in 32 (54.2%) of these patients. There were no significant differences in PFS and OS between the ASCT and non-ASCT groups for all patients (n=59) and for patients with PTCL-NOS (n=26). However, in patients with AITL, the ASCT group was associated with significantly better PFS than the non-ASCT group, although there was no significant difference in OS.
Conclusion
The current study demonstrated that the survival outcomes with the current treatment options remain poor for patients with PTCL-NOS. Upfront ASCT may provide a survival benefit for patients with AITL, but not PTCL-NOS.

Citations

Citations to this article as recorded by

Successful Treatment, with Chemotherapy and Intravenous Administration of Ascorbic Acid, of a Patient with Peripheral T-Cell Lymphoma, Not Otherwise Specified
Chiaki Tokoro, Atsushi Tashiro, Kenji Ina, Yoshiteru Tanaka, Hiroyuki Kobayakawa, Takashi Yoshida, Satoshi Kayukawa
Journal of Cancer Research Updates.2024; 13: 1. CrossRef
Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis
L. Girard, Y. J. Koh, L. P. Koh, Y. L. Chee, H. L. Chan, J. Lee, S. de Mel, L. M. Poon, M. Samuel
Bone Marrow Transplantation.2024; 59(6): 838. CrossRef
Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances
Luís Alberto de Pádua Covas Lage, Hebert Fabricio Culler, Cadiele Oliana Reichert, Sheila Aparecida Coelho da Siqueira, Juliana Pereira
Frontiers in Oncology.2023;[Epub] CrossRef
Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma
Qingyang Zhang, Le Yin, Qinqiao Lai, Yan Zhao, Hongling Peng
Clinical and Experimental Medicine.2023; 23(8): 4219. CrossRef

5,792 View
209 Download
3 Web of Science
4 Crossref

Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts: Jun Ho Yi, Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Youngil Koh, Jin Seok Kim, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Whan Jung Yun, Yong Park, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Dae-Sik Hong, Ho-Sup Lee, Gyeong-Won Lee, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2023;55(1):325-333. Published online April 22, 2022; DOI: https://doi.org/10.4143/crt.2022.008

Abstract PDF PubReader ePub

Purpose
Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.
Materials and Methods
We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.
Results
Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).
Conclusion
In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.

Citations

Citations to this article as recorded by

PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
Peng Sun, Hong Cen, Haiyan Yang, Rui Huang, Zhen Cai, Xuekui Gu, Hanying Bao, Zusheng Xu, Zuhong Xu, Zhi-Ming Li
Cancer Cell International.2025;[Epub] CrossRef
Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
Ya Hwee Tan, Dok Hyun Yoon, Andrew J. Davies, Christian Buske, Yang Liang Boo, Nagavalli Somasundaram, Francesca Lim, Shin Yeu Ong, Anand Jeyasekharan, Koji Izutsu, Won Seog Kim, Jason Yongsheng Chan
Discover Oncology.2025;[Epub] CrossRef
Recent advances in cellular immunotherapy for lymphoid malignancies
Haerim Chung, Hyunsoo Cho
Blood Research.2023; 58(4): 166. CrossRef
Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases
Hongyu Chen, Junmin Wang, Caiyun Zhang, Peilun Ding, Shuxia Tian, Junming Chen, Guang Ji, Tao Wu
Biomedicine & Pharmacotherapy.2022; 153: 113341. CrossRef

8,145 View
369 Download
3 Web of Science
4 Crossref

A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK: Sora Kang, Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Jung Sun Park, Yoon Sei Lee, Chan-Sik Park, Heounjeong Go, Jooryung Huh, Jin Sook Ryu, Sang-Wook Lee, Seok Jin Kim, Won Seog Kim, Sang Eun Yoon, Young Hyeh Ko, Cheolwon Suh; Cancer Res Treat. 2023;55(1):314-324. Published online March 31, 2022; DOI: https://doi.org/10.4143/crt.2022.015

Abstract PDF Supplementary Material PubReader ePub

Purpose
Prognostic Index for Natural Killer Lymphoma (PINK) is the most widely accepted prognostic model for patients withextranodal natural killer/T-cell lymphoma (ENKTL) treated with non-anthracycline–based therapy. We aimed to evaluate the prognostic implications of serum β-2 microglobulin (β2M) in the context of PINK and proposed a new prognostic model.
Materials and Methods
A total of 138 patients who were newly diagnosed with ENKTL and treated with non-anthracycline-based chemotherapy were identified. The cut-off value of high serum β2M was calculated by maximal-chi square methods (4.1 mg/L). A new prognostic model incorporating serum β2M into PINK was proposed and validated in an independent validation cohort (n=88).
Results
The patients’ median age was 53.5 years (range, 19 to 80 years). Patients with high serum β2M levels had significantly worse overall survival (OS) and progression-free survival (PFS). In multivariate analysis, high serum β2M was an independent adverse prognostic factor for OS. A new PINK-B (Prognostic Index for Natural Killer Lymphoma-serum β-2 microglobulin) model stratifiedpatients into three groups with distinct OS and PFS in the training cohort (3-year OS, 84.1% [95% confidence interval, 75.1 to 94.2], 46.8% [36.1 to 60.8] and 17.6% [6.3 to 49.2] for the low-, intermediate, and high-risk groups, respectively; 3-year PFS, 70.6% [59.4 to 83.8], 35.9% [25.9 to 49.8], and 7.35% [1.1 to 46.7] for the low-, intermediate-, and high-risk groups, respectively). The PINK-B model was further validated in an independent cohort.
Conclusion
Serum β2M is an independent prognostic factor for ENKTL patients. The new serum β2M-based prognostic model may be useful for identifying ultra-high-risk patients, and it can easily be adopted into daily clinical practice.

Citations

Citations to this article as recorded by

Elevated serum IL-6 and total IgEAb are associated with poor survival in natural killer/T-cell lymphoma
Yun Hui, Yingjun Gao, Jiawei Li, Qingtao Kong, Yuanyuan Duan, Haibo Liu, Fang Liu, Hong Sang
Annals of Hematology.2024; 103(4): 1285. CrossRef
Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients
Theodoros P. Vassilakopoulos, Maria Arapaki, Panagiotis T. Diamantopoulos, Athanasios Liaskas, Fotios Panitsas, Marina P. Siakantaris, Maria Dimou, Styliani I. Kokoris, Sotirios Sachanas, Marina Belia, Chrysovalantou Chatzidimitriou, Elianna A. Konstantin
Cancers.2024; 16(2): 238. CrossRef
Prognostic Value of18F-FDG PET/CT Radiomics in Extranodal Nasal-Type NK/T Cell Lymphoma
Yu Luo, Zhun Huang, Zihan Gao, Bingbing Wang, Yanwei Zhang, Yan Bai, Qingxia Wu, Meiyun Wang
Korean Journal of Radiology.2024; 25(2): 189. CrossRef
A novel prognostic index for extranodal natural killer/T-cell lymphoma in the era of pegaspargase/L-asparaginase
Ziyuan Shen, Xudong Zhang, Yujie Li, Xicheng Chen, Xing Xing, Hao Zhang, Jingjing Ye, Ling Wang, Tao Jia, Taigang Zhu, Yuqing Miao, Chunling Wang, Hui Liu, Liang Wang, Wei Sang
Future Oncology.2024; 20(28): 2071. CrossRef

5,368 View
133 Download
5 Web of Science
4 Crossref

Circulating Tumor DNA–Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas: Seok Jin Kim, Yeon Jeong Kim, Sang Eun Yoon, Kyung Ju Ryu, Bon Park, Donghyun Park, Duck Cho, Hyun-Young Kim, Junhun Cho, Young Hyeh Ko, Woong-Yang Park, Won Seog Kim; Cancer Res Treat. 2023;55(1):291-303. Published online March 2, 2022; DOI: https://doi.org/10.4143/crt.2022.017

Abstract PDF Supplementary Material PubReader ePub

Purpose
Plasma circulating tumor DNA (ctDNA) could reflect the genetic alterations present in tumor tissues. However, there is little information about the clinical relevance of cell-free DNA genotyping in peripheral T-cell lymphoma (PTCL).
Materials and Methods
After targeted sequencing plasma cell-free DNA of patients with various subtypes of PTCL (n=94), we analyzed the mutation profiles of plasma ctDNA samples and their predictive value of dynamic ctDNA monitoring for treatment outcomes.
Results
Plasma ctDNA mutations were detected in 53 patients (56%, 53/94), and the detection rate of somatic mutations was highest in angioimmunoblastic T-cell lymphoma (24/31, 77%) and PTCL, not otherwise specified (18/29, 62.1%). Somatic mutations were detected in 51 of 66 genes that were sequenced, including the following top 10 ranked genes: RHOA, CREBBP, KMT2D, TP53, IDH2, ALK, MEF2B, SOCS1, CARD11, and KRAS. In the longitudinal assessment of ctDNA mutation, the difference in ctDNA mutation volume after treatment showed a significant correlation with disease relapse or progression. Thus, a ≥ 1.5-log decrease in genome equivalent (GE) between baseline and the end of treatment showed a significant association with better survival outcomes than a < 1.5-log decrease in GE.
Conclusion
Our results suggest the clinical relevance of plasma ctDNA analysis in patients with PTCL. However, our findings should be validated by a subsequent study with a larger study population and using a broader gene panel.

Citations

Citations to this article as recorded by

Clinical use of circulating tumor DNA analysis in patients with lymphoma
Bettina Bisig, Karine Lefort, Sylvain Carras, Laurence de Leval
Human Pathology.2025; 156: 105679. CrossRef
Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma
Seok Jin Kim, Jin Ju Kim, Mi Ri Park, Bon Park, Kyung Ju Ryu, Sang Eun Yoon, Won Seog Kim, Saeam Shin, Seung-Tae Lee
Annals of Laboratory Medicine.2025; 45(1): 90. CrossRef
Circulating tumor DNA in lymphoma: technologies and applications
Lina Fu, Xuerong Zhou, Xiaoyu Zhang, Xuhua Li, Fan Zhang, Hongcang Gu, Xiaoxue Wang
Journal of Hematology & Oncology.2025;[Epub] CrossRef
Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside
Mohammad Almasri, Nawar Maher, Bashar Al Deeban, Ndeye Marie Diop, Riccardo Moia, Gianluca Gaidano
International Journal of Molecular Sciences.2025; 26(10): 4869. CrossRef
Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application
Zongyao Huang, Yao Fu, Hong Yang, Yehan Zhou, Min Shi, Qingyun Li, Weiping Liu, Junheng Liang, Liuqing Zhu, Sheng Qin, Huangming Hong, Yang Liu
Molecular Cancer.2024;[Epub] CrossRef
Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma
Sang Eun Yoon, Seung-Ho Shin, Dae Keun Nam, Junhun Cho, Won Seog Kim, Seok Jin Kim
Cancer Research and Treatment.2024; 56(3): 920. CrossRef
Minimal residual disease detection in lymphoma: methods, procedures and clinical significance
Sijun Zhang, Xiangyu Wang, Zhenzhen Yang, Mengjie Ding, Mingzhi Zhang, Ken H. Young, Xudong Zhang
Frontiers in Immunology.2024;[Epub] CrossRef
Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future
Jun-Ying Li, Li-Ping Zuo, Jian Xu, Chun-Yan Sun
Blood Reviews.2024; 68: 101237. CrossRef
A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas
Laurence de Leval, Philippe Gaulard, Ahmet Dogan
Blood.2024; 144(18): 1855. CrossRef
In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas
Jin Ju Kim, Hyun-Young Kim, Zisun Choi, So yoon Hwang, Hansol Jeong, Jong Rak Choi, Sang Eun Yoon, Won Seog Kim, Sun-Hee Kim, Hee-Jin Kim, Sang-Yong Shin, Seung-Tae Lee, Seok Jin Kim
Frontiers in Oncology.2023;[Epub] CrossRef
Circulating tumor DNA in NK/T and peripheral T cell lymphoma
Yu-Jia Huo, Wei-Li Zhao
Seminars in Hematology.2023; 60(3): 173. CrossRef
A genetic profiling guideline to support diagnosis and clinical management of lymphomas
Margarita Sánchez-Beato, Miriam Méndez, María Guirado, Lucía Pedrosa, Silvia Sequero, Natalia Yanguas-Casás, Luis de la Cruz-Merino, Laura Gálvez, Marta Llanos, Juan Fernando García, Mariano Provencio
Clinical and Translational Oncology.2023; 26(5): 1043. CrossRef

7,128 View
309 Download
12 Web of Science
12 Crossref

Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study: Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Hye Jin Kang, Youngil Koh, Gyeong-Won Lee, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Hwan Jung Yun, Jun Ho Yi, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Shin Young Hyun, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Se-Hyung Kim, Ho-Sup Lee, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2022;54(4):1268-1277. Published online December 30, 2021; DOI: https://doi.org/10.4143/crt.2021.1168

Abstract PDF Supplementary Material PubReader ePub: Purpose
Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP).
Materials and methods
We conducted a prospective cohort study to evaluate the effectiveness of pegfilgrastim prophylaxis in DLBCL patients receiving R-CHOP, and we compared them with the PROCESS cohort (n=485).
Results
Since January 2015, 986 patients with DLBCL were enrolled. Pegfilgrastim was administered at least once in 930 patients (94.3%), covering 90.3% of all cycles. FN developed in 137 patients (13.9%) in this cohort (23.7% in the PROCESS cohort, p<0.001), and 4.2% of all cycles (10.2% in the PROCESS cohort, p<0.001). Dose delay was less common (≥3 days: 18.1% vs. 23.7%, p=0.015; ≥5 days: 12.0% vs. 18.3%, p=0.023) in this cohort than in the PROCESS cohort. The incidence of TRM (3.2% vs. 5.6%, p=0.047) and infection-related death (1.8% vs. 4.5%, p=0.004) was lower in this cohort than in the PROCESS cohort. The 4-year overall survival (OS) and progression-free survival (PFS) rates of the two cohorts were not different (OS: 73.0% vs. 71.9%, p=0.545; PFS: 69.5% vs. 68.8%, p=0.616). However, in patients aged ≥75 years, the 4-year OS and PFS rates were higher in this cohort than in the PROCESS cohort (OS: 49.6% vs. 33.7%, p=0.032; PFS: 44.2% vs. 30.3% p=0.047).
Conclusion
Pegfilgrastim prophylaxis is effective in the prevention of FN and infection-related death in DLBCL patients receiving R-CHOP, and it also improves OS in patients aged ≥75 years.

8,177 View
304 Download
2 Web of Science

Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma: Sang Eun Yoon, Yeon Jeong Kim, Joon Ho Shim, Donghyun Park, Junhun Cho, Young Hyeh Ko, Woong-Yang Park, Yeung-Chul Mun, Kyoung Eun Lee, Duck Cho, Won Seog Kim, Seok Jin Kim; Cancer Res Treat. 2022;54(2):597-612. Published online July 23, 2021; DOI: https://doi.org/10.4143/crt.2021.752

Abstract PDF Supplementary Material PubReader ePub

Purpose
Analysis of circulating tumor DNA (ctDNA) in blood could allow noninvasive genetic analysis of primary tumors. Although there have been unmet needs for noninvasive methods in patients with primary central nervous system lymphoma (PCNSL), it is still not determined whether plasma ctDNA analysis could be useful for patients with PCNSL.
Materials and Methods
Targeted deep sequencing of 54 genes was performed in cell-free DNA isolated from plasma samples collected pretreatment, during treatment, and at the end of treatment in 42 consecutively diagnosed PCNSL patients between January 2017 and December 2018.
Results
Targeted sequencing of plasma cell-free DNA detected somatic mutations representing ctDNA in 11 cases (11/41, 27%). The detection of ctDNA was not related to the concentration of cell-free DNA or tumor volume. The mutation profiles of these 11 cases varied between patients. The most frequently mutated gene was PIM1 (4/11, 36.4%), whereas KMT2D, PIK3CA, and MYD88 were each observed in three patients (3/11, 27%). The mutations of 13 genes were concordantly found in primary tumor tissue and plasma ctDNA, giving a detection sensitivity of 45%. During the serial tracking of seven patients with complete response, the disappearance of ctDNA mutations was found in four patients, whereas three patients had detected ctDNA mutation at the end of treatment.
Conclusion
The plasma ctDNA mutation analysis still has limited value for surveillance and predicting treatment outcomes of PCNSL because the detection efficiency was lower than other systemic lymphomas. Thus, analytical platforms should be improved to overcome anatomical hurdles associated with PCNSL.

Citations

Citations to this article as recorded by

Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma
Seok Jin Kim, Jin Ju Kim, Mi Ri Park, Bon Park, Kyung Ju Ryu, Sang Eun Yoon, Won Seog Kim, Saeam Shin, Seung-Tae Lee
Annals of Laboratory Medicine.2025; 45(1): 90. CrossRef
Circulating tumor DNA in lymphoma: technologies and applications
Lina Fu, Xuerong Zhou, Xiaoyu Zhang, Xuhua Li, Fan Zhang, Hongcang Gu, Xiaoxue Wang
Journal of Hematology & Oncology.2025;[Epub] CrossRef
Reliable detection of CNS lymphoma-derived circulating tumor DNA in cerebrospinal fluid using multi-biomarker NGS profiling: insights from a real-world study
Veronika Navrkalova, Andrea Mareckova, Samuel Hricko, Viera Hrabcakova, Lenka Radova, Vaclav Kubes, Jakub Porc, Tomas Reigl, Sarka Pospisilova, Jana Kotaskova, Andrea Janikova
Biomarker Research.2025;[Epub] CrossRef
Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR
Yujie Zhong, Geok Wee Tan, Johanna Bult, Nick Veltmaat, Wouter Plattel, Joost Kluiver, Roelien Enting, Arjan Diepstra, Anke van den Berg, Marcel Nijland
BMC Cancer.2024;[Epub] CrossRef
Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma
Jin-Hua Liang, Yi-Fan Wu, Hao-Rui Shen, Yue Li, Jun-Heng Liang, Rui Gao, Wei Hua, Chun-Yu Shang, Kai-Xin Du, Tong-Yao Xing, Xin-Yu Zhang, Chen-Xuan Wang, Liu-Qing Zhu, Yang W. Shao, Jian-Yong Li, Jia-Zhu Wu, Hua Yin, Li Wang, Wei Xu
Leukemia.2024; 38(7): 1541. CrossRef
Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review
Lakshmi Nayak, Chetan Bettegowda, Florian Scherer, Norbert Galldiks, Manmeet Ahluwalia, Alexander Baraniskin, Louisa von Baumgarten, Jacoline E C Bromberg, Andrés J M Ferreri, Christian Grommes, Khê Hoang-Xuan, Julia Kühn, James L Rubenstein, Roberta Rudà
Neuro-Oncology.2024; 26(6): 993. CrossRef
Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma
Sang Eun Yoon, Seung-Ho Shin, Dae Keun Nam, Junhun Cho, Won Seog Kim, Seok Jin Kim
Cancer Research and Treatment.2024; 56(3): 920. CrossRef
Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future
Jun-Ying Li, Li-Ping Zuo, Jian Xu, Chun-Yan Sun
Blood Reviews.2024; 68: 101237. CrossRef
Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas
Jurik A. Mutter, Stefan K. Alig, Mohammad S. Esfahani, Eliza M. Lauer, Jan Mitschke, David M. Kurtz, Julia Kühn, Sabine Bleul, Mari Olsen, Chih Long Liu, Michael C. Jin, Charles W. Macaulay, Nicolas Neidert, Timo Volk, Michel Eisenblaetter, Sebastian Raue
Journal of Clinical Oncology.2023; 41(9): 1684. CrossRef
Clinical applications of circulating tumor DNA in central nervous system lymphoma
Anna Katharina Foerster, Eliza M. Lauer, Florian Scherer
Seminars in Hematology.2023; 60(3): 150. CrossRef
Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease
Gloria Figaredo, Alejandro Martín-Muñoz, Santiago Barrio, Laura Parrilla, Yolanda Campos-Martín, María Poza, Laura Rufián, Patrocinio Algara, Marina De La Torre, Ana Jiménez Ubieto, Joaquín Martínez-López, Luis-Felipe Casado, Manuela Mollejo
Cancers.2023; 15(16): 4022. CrossRef
Asian variant intravascular large B-cell lymphoma with highly suspected central nervous system involvement: A case report
Yong-Pyo Lee, Seung-Myoung Son, Jihyun Kwon
World Journal of Clinical Cases.2023; 11(33): 8058. CrossRef
The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies
Rafael Colmenares, Noemí Álvarez, Santiago Barrio, Joaquín Martínez-López, Rosa Ayala
Cancers.2022; 14(5): 1310. CrossRef

8,507 View
302 Download
13 Web of Science
13 Crossref

Hematologic Malignancy

Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels: Hyung-Don Kim, Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Jung Sun Park, Chan-Sik Park, Jooryung Huh, Jin Sook Ryu, Sang-Wook Lee, Dok-Hyun Yoon, Seok Jin Kim, Young Hyeh Ko, Won Seog Kim, Cheolwon Suh; Cancer Res Treat. 2021;53(3):847-856. Published online December 17, 2020; DOI: https://doi.org/10.4143/crt.2020.1060

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to investigate the prognostic value of serum β2-microglobulin for patients with Burkitt lymphoma (BL) and to propose a risk-stratifying classification system.
Materials and Methods
A prospective registry-based cohort study of BL patients treated with dose-intensive or effective dose-adjusted chemotherapies (n=81) was conducted. Survival outcomes were compared based on previously reported risk groups and/or serum β2-microglobulin levels. A risk-stratifying classification system incorporating serum β2-microglobulin levels was proposed and validated in an independent validation cohort (n=60).
Results
The median age was 47 years, and 57 patients (70.4%) were male. Patients with high serum β2-microglobulin levels (> 2 mg/L) had significantly worse progression-free survival (PFS) and overall survival (OS) (p < 0.01 for both). Serum β2-microglobulin levels further stratified patients in the low-risk and high-risk groups in terms of PFS (p=0.010 and p=0.044, respectively) and OS (p=0.014 and p=0.026, respectively). Multivariate analyses revealed that a high serum β2-microglobulin level (> 2 mg/L) was independently associated with a shorter PFS (hazards ratio [HR], 3.56; p=0.047) and OS (HR, 4.66; p=0.043). The new classification system incorporating the serum β2-microglobulin level allowed the stratification of patients into three distinct risk subgroups with 5-year OS rates of 100%, 89.5%, and 62.5%. In an independent cohort of BL, the system was validated by stratifying patients with different survival outcomes.
Conclusion
Serum β2-microglobulin level is an independent prognostic factor for BL patients. The proposed β2-microglobulin–based classification system could stratify patients with distinct survival outcomes, which may help define appropriate treatment approaches for individual patients.

Citations

Citations to this article as recorded by

Prognostic Factors for Survival in Adults With Burkitt Lymphoma: A Systematic Review
Aythami de Armas‐Castellano, Diego Infante‐Ventura, Tasmania del Pino‐Sedeño, Yadira González Hernández, Raul Quiros, Beatriz León‐Salas, Vincent Ribrag, María M. Trujillo‐Martín
Cancer Medicine.2025;[Epub] CrossRef
Predictive Value of Serum β2-Microglobulin for 28-Day Mortality in Sepsis Patients in the Emergency Department
Xiangqun Zhang, Long Yang, Yu Gu, Junyuan Wu, Xue Mei, Shubin Guo
Infection and Drug Resistance.2025; Volume 18: 2365. CrossRef
The clinical significance and prognostic value of serum beta-2 microglobulin in adult lymphoma-associated hemophagocytic lymphohistiocytosis: a multicenter analysis of 326 patients
Ze Jin, Yi Miao, Jie Zhang, Jing Zhang, Chunling Wang, Xuzhang Lu, Yuqing Miao, Miao Sun, Yunping Zhang, Yun Zhuang, Haiwen Ni, Jingyan Xu, Wanchuan Zhuang, Min Zhao, Jianfeng Zhu, Min Xu, Guoqiang Lin, Haiying Hua, Xiaoyan Xie, Maozhong Xu, Tao Jia, Liji
Annals of Hematology.2024; 103(7): 2257. CrossRef
Prognostic Value of18F-FDG PET/CT Radiomics in Extranodal Nasal-Type NK/T Cell Lymphoma
Yu Luo, Zhun Huang, Zihan Gao, Bingbing Wang, Yanwei Zhang, Yan Bai, Qingxia Wu, Meiyun Wang
Korean Journal of Radiology.2024; 25(2): 189. CrossRef
The Role of Beta2-Microglobulin in Central Nervous System Disease
Zhen-Yuan Liu, Feng Tang, Jin-Zhou Yang, Xi Chen, Ze-Fen Wang, Zhi-Qiang Li
Cellular and Molecular Neurobiology.2024;[Epub] CrossRef
Serum beta2-microglobulin acts as a biomarker for severity and prognosis in glioma patients: a preliminary clinical study
Zhen-Yuan Liu, Feng Tang, Jing Wang, Jin-Zhou Yang, Xi Chen, Ze-Fen Wang, Zhi-Qiang Li
BMC Cancer.2024;[Epub] CrossRef
Serum beta2-microglobulin and peripheral blood eosinophils for the assessment of severity and prognosis with omicron variant COVID-19 infection
Jie Tan, Hanxi Fang, Xiao Hu, Ming Yue, Junling Yang
Frontiers in Molecular Biosciences.2024;[Epub] CrossRef
A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis
Zhentian Wu, Chenyi Wang, Yao Lyu, Zheshen Lin, Ming Lu, Shixiong Wang, Bingxuan Wang, Na Yang, Yeye Li, Jianhong Wang, Xiaohui Duan, Na Zhang, Jing Gao, Yuan Zhang, Miaowang Hao, Zhe Wang, Guangxun Gao, Rong Liang
Frontiers in Oncology.2023;[Epub] CrossRef
Beta2-microglobulin is a valuable marker and identifies a poor-prognosis subgroup among intermediate-risk patients with diffuse large B cell lymphoma
Ning-Chun Chen, Hung Chang, Hsiao-Wen Kao, Che-Wei Ou, Ming-Chung Kuo, Po-Nan Wang, Tung-Liang Lin, Jin-Hou Wu, Yu-Shin Hung, Yi-Jiun Su, Yuen-Chin Ong, Hsuan-Jen Shih
Clinical and Experimental Medicine.2023; 23(7): 3759. CrossRef
Tuberculosis combined with Burkitt lymphoma in a kidney transplant recipient: A case report and literature review
Jian-Nan Hu, Mu-Qing Yu, Li-Juan Hua, Chen Bao, Qian Liu, Chao Liu, Zi-Ling Li, Xi Wang, Shu-Yun Xu
Medicine.2023; 102(18): e33671. CrossRef
Elevated serum beta-2 microglobulin level predicts short-term poor prognosis of patients with de novo acute omicron variant COVID-19 infection
Shengping Gong, Ruishuang Ma, Ting Zhu, Xiaoqin Ge, Rongrong Xie, Qingsong Tao, Cong Shi
Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef
An Externally Validated Nomogram for Predicting the Overall Survival of Patients With Diffuse Large B-Cell Lymphoma Based on Clinical Characteristics and Systemic Inflammatory Markers
Yajiao Liu, Li Sheng, Haiying Hua, Jingfen Zhou, Ying Zhao, Bei Wang
Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
Prognostic significance of serum β2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified
Hyung-Don Kim, Hyungwoo Cho, Byeong Seok Sohn, Chan-Sik Park, Jooryung Huh, Jin Sook Ryu, Sang-Wook Lee, Sang Eun Yoon, Seok Jin Kim, Young Hyeh Ko, Won Seog Kim, Cheolwon Suh
Leukemia & Lymphoma.2022; 63(1): 124. CrossRef

6,353 View
151 Download
13 Web of Science
13 Crossref

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial: Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Hye Jin Kang, Hye Won Lee, Hyeon-Seok Eom, Jung Yong Hong, Junhun Cho, Young Hyeh Ko, Jooryung Huh, Woo-Ick Yang, Weon Seo Park, Seung-Sook Lee, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2020;52(2):374-387. Published online August 13, 2019; DOI: https://doi.org/10.4143/crt.2019.198

Abstract PDF PubReader ePub

Purpose
The treatment outcome of brentuximab vedotin (BV) has not been related with CD30 expression in previous studies enrolling patients with a wide range of CD30 expression level. Thus, this study explored the efficacy of BV in high-CD30–expressing non-Hodgkin lymphoma (NHL) patients most likely to benefit.
Materials and Methods
This phase II study (Clinicaltrials.gov: NCT02280785) enrolled relapsed or refractory high-CD30–expressing NHL, with BV administered intravenously at 1.8 mg/kg every 3 weeks. The primary endpoint was > 40% disease control rate, consisting of complete response (CR), partial response (PR), or stable disease. We defined high CD30 expression as ≥ 30% tumor cells positive for CD30 by immunohistochemistry.
Results
High-CD30-expressing NHL patients (n=33) were enrolled except anaplastic large cell lymphoma. The disease control rate was 48.5% (16/33) including six CR and six PR; six patients (4CR, 2PR) maintained their response over 16 completed cycles. Response to BV and survival were not associated with CD30 expression levels. Over a median of 29.2 months of follow-up, the median progression-free and overall survival rates were 1.9 months and 6.1 months, respectively. The most common adverse events were fever (39%), neutropenia (30%), fatigue (24%), and peripheral sensory neuropathy (27%). In a post-hoc analysis for the association of multiple myeloma oncogene 1 (MUM1) on treatment outcome, MUM1- negative patients showed a higher response (55.6%, 5/9) than MUM1-positive patients (13.3%, 2/15).
Conclusion
BV performance as a single agent was acceptable in terms of disease control rates and toxicity profiles, especially MUM1-negative patients.

Citations

Citations to this article as recorded by

Viral oncogenesis in cancer: from mechanisms to therapeutics
Qing Xiao, Yi Liu, Tingting Li, Chaoyu Wang, Sanxiu He, Liuyue Zhai, Zailin Yang, Xiaomei Zhang, Yongzhong Wu, Yao Liu
Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef
CD30 associates with EBER-EBV but not HCV-NS3 in T-cell non-Hodgkin lymphoma
Rizki Amalia Juwita, Lili Ananta Saputra, Ika Fiilasari, Mardiah Suci Hardianti, Nungki Anggorowati
Frontiers in Virology.2025;[Epub] CrossRef
Unusual lymphomas: Unusual sites
Ajay Joseph Kaveripakam, Meetu Agrawal, Kaushal Kalra, Sana Ahuja, Neha Kawatra Madan
Journal of Hematology and Allied Sciences.2025; 0: 1. CrossRef
Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review
Mohammad Sadegh Fallahi, Nasibeh Zerangian, Atousa Ghorbani, Gisou Erabi, Melika Shirali, Elaheh Shabani, Foad Rommasi, Mahsa Mohammadi Najafabadi, Shima Karbasi, Samaneh Toutounchian, Ramin Ahangar-Sirous, Ava Motaghy, Mahsa Heidari, Niloofar Deravi
Current Cancer Therapy Reviews.2024; 20(1): 53. CrossRef
Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30‐positive cutaneous T‐cell lymphoma
Yoji Hirai, Jun Sakurai, Shiho Yoshida, Takashi Kikuchi, Toshiharu Mitsuhashi, Tomoko Miyake, Taku Fujimura, Riichiro Abe, Hiroki Fujikawa, Hikari Boki, Hiraku Suga, Sayaka Shibata, Tomomitsu Miyagaki, Takatoshi Shimauchi, Eiji Kiyohara, Yoshio Kawakami,
The Journal of Dermatology.2024; 51(8): 1037. CrossRef
Brentuximab vedotin therapy followed by autologous peripheral stem cell transplantation as a viable treatment option for an older adult with transformed lymphoma: a case report and literature review
Jiewen Tan, Jinman Zhong, Wanzhen Hu, Guobiao Wu, Chong Zeng, Dan Xiong
Journal of International Medical Research.2024;[Epub] CrossRef
Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies
Roxanne C. Jewell, Richard J. Mills, Colm Farrell, Sandra A. G. Visser
British Journal of Clinical Pharmacology.2024;[Epub] CrossRef
Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma
Chengji Wang, Liang Wang
Chinese Medical Journal.2024; 137(19): 2308. CrossRef
Research progress on EBV-associated NK/T cell lymphoma
Jun CAI, Yi CAO, LiYun QIU, Yan GAO, HuiQiang HUANG, QingQing CAI
SCIENTIA SINICA Vitae.2024; 54(12): 2363. CrossRef
Treatment of extranodal NK/T-cell lymphoma: From past to future
Zheng Yan, Shuna Yao, Zhizhong Wang, Wenping Zhou, Zhihua Yao, Yanyan Liu
Frontiers in Immunology.2023;[Epub] CrossRef
Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma
Ajay Major, Pierluigi Porcu, Bradley M. Haverkos
Cancers.2023; 15(5): 1366. CrossRef
Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
Susan Y. Wu, Penny Q. Fang, Ethan B. Wang, Sairah Ahmed, Madeleine Duvic, Preetesh Jain, Luis E. Malpica Castillo, Ranjit Nair, Raphael E. Steiner, Paolo Strati, Auris O. Huen, Swaminathan P. Iyer, Chelsea C. Pinnix, Bouthaina S. Dabaja, Jillian R. Gunthe
Advances in Radiation Oncology.2023; 8(6): 101279. CrossRef
Novel target and treatment agents for natural killer/T-cell lymphoma
Xiao-Peng Tian, Yi Cao, Jun Cai, Yu-Chen Zhang, Qi-Hua Zou, Jin-Ni Wang, Yu Fang, Jia-Hui Wang, Song-Bin Guo, Qing-Qing Cai
Journal of Hematology & Oncology.2023;[Epub] CrossRef
Treatment‐related adverse events of antibody‐drug conjugates in clinical trials: A systematic review and meta‐analysis
Jinming Li, Guoshuang Shen, Zhen Liu, Yaobang Liu, Miaozhou Wang, Fuxing Zhao, Dengfeng Ren, Qiqi Xie, Zitao Li, Zhilin Liu, Yi Zhao, Fei Ma, Xinlan Liu, Zhengbo Xu, Jiuda Zhao
Cancer Innovation.2023; 2(5): 346. CrossRef
Advances and challenges of immunotherapies in NK/T cell lymphomas
Ling He, Na Chen, Lei Dai, Xingchen Peng
iScience.2023; 26(11): 108192. CrossRef
Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study
Xudong Zhang, Honghan Qiao, Xiaofei Chai, Xue Gao, Rongjun Ma, Yufu Li, Zunmin Zhu, Mingzhi Zhang
Cancer Medicine.2023; 12(24): 21725. CrossRef
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study
Seok Jin Kim, Young Rok Do, Ho-Sup Lee, Won-Sik Lee, Jee Hyun Kong, Jae-Yong Kwak, Hyeon-Seok Eom, Joon Ho Moon, Jun Ho Yi, Jeong-Ok Lee, Jae-Cheol Jo, Deok-Hwan Yang
Blood Research.2023; 58(4): 194. CrossRef
Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
Ka-Hei (Murphy) Sun, Yin-Ting (Heylie) Wong, Ka-Man (Carmen) Cheung, Carmen (Michelle) Yuen, Yun-Tat (Ted) Chan, Wing-Yan (Jennifer) Lai, Chun (David) Chao, Wing-Sum (Katie) Fan, Yuen-Kiu (Karen) Chow, Man-Fai Law, Ho-Chi (Tommy) Tam
Diagnostics.2022; 12(2): 409. CrossRef
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
Jeffrey P. Ward, Melissa M. Berrien-Elliott, Felicia Gomez, Jingqin Luo, Michelle Becker-Hapak, Amanda F. Cashen, Nina D. Wagner-Johnston, Kami Maddocks, Matthew Mosior, Mark Foster, Kilannin Krysiak, Alina Schmidt, Zachary L. Skidmore, Sweta Desai, Marcu
Blood.2022; 139(13): 1999. CrossRef
Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
Sotirios G. Papageorgiou, Thomas P. Thomopoulos, Athanasios Liaskas, Theodoros P. Vassilakopoulos
Cancers.2022; 14(8): 1917. CrossRef
Basic immunohistochemistry for lymphoma diagnosis
Junhun Cho
Blood Research.2022; 57(S1): S55. CrossRef
Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
John C. Reneau, Polina Shindiapina, Zachary Braunstein, Youssef Youssef, Miguel Ruiz, Saira Farid, Walter Hanel, Jonathan E. Brammer
Journal of Clinical Medicine.2022; 11(10): 2699. CrossRef
CD30 + Primary intestinal T-cell lymphoma (unclassified) masquerading as chronic inflammation: a case report
Kashif Osmani, Eshana Shah, Bradley Drumheller, Shaun Webb, Manmeet Singh, Paul Rubinstein, John Patrick Galvin, Megan S. Lim, Carlos Murga-Zamalloa
Diagnostic Pathology.2022;[Epub] CrossRef
EBV-associated NK and T-cell lymphoid neoplasms
Hiroshi Kimura, Laurence de Leval, Qingqing Cai, Won Seog Kim
Current Opinion in Oncology.2022; 34(5): 422. CrossRef
Intravascular NK/T-Cell Lymphoma: What We Know about This Diagnostically Challenging, Aggressive Disease
Magda Zanelli, Paola Parente, Francesca Sanguedolce, Maurizio Zizzo, Andrea Palicelli, Alessandra Bisagni, Illuminato Carosi, Domenico Trombetta, Luca Mastracci, Linda Ricci, Saverio Pancetti, Giovanni Martino, Giuseppe Broggi, Rosario Caltabiano, Alberto
Cancers.2022; 14(21): 5458. CrossRef
Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management
Eric Tse, Christopher P. Fox, Alexander Glover, Sang Eun Yoon, Won Seog Kim, Yok-Lam Kwong
Seminars in Hematology.2022; 59(4): 198. CrossRef
Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions
Huan Chen, Tao Pan, Yizi He, Ruolan Zeng, Yajun Li, Liming Yi, Hui Zang, Siwei Chen, Qintong Duan, Ling Xiao, Hui Zhou
Frontiers in Oncology.2021;[Epub] CrossRef
NK-/T-cell lymphomas
Hua Wang, Bi-bo Fu, Robert Peter Gale, Yang Liang
Leukemia.2021; 35(9): 2460. CrossRef
The landscape of new drugs in extranodal NK/T-cell lymphoma
Liang Wang, Lin-Rong Li, Luo Zhang, Jing-Wen Wang
Cancer Treatment Reviews.2020; 89: 102065. CrossRef
Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma
Caiqin Xie, Xian Li, Hui Zeng, Wenbin Qian
Experimental Hematology & Oncology.2020;[Epub] CrossRef
New agents and regimens for diffuse large B cell lymphoma
Liang Wang, Lin-rong Li, Ken H. Young
Journal of Hematology & Oncology.2020;[Epub] CrossRef
A Phase II Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive- and CD30-Positive Lymphomas
Miso Kim, Jeong-Ok Lee, Jiwon Koh, Tae Min Kim, Ji Yun Lee, Yoon Kyung Jeon, Bhumsuk Keam, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heo
SSRN Electronic Journal .2020;[Epub] CrossRef

10,620 View
634 Download
30 Web of Science
32 Crossref

Body Cavity–Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma: Junghoon Shin, Young Hyeh Ko, Sung Yong Oh, Dok Hyun Yoon, Jeong-Ok Lee, Jin Seok Kim, Yong Park, Ho Jin Shin, Seok Jin Kim, Jong Ho Won, Sung-Soo Yoon, Won Seog Kim, Youngil Koh, On behalf of the Consortium for Improving Survival of Lymphoma investigators; Cancer Res Treat. 2019;51(4):1302-1312. Published online February 14, 2019; DOI: https://doi.org/10.4143/crt.2018.555

Abstract PDF PubReader ePub

Purpose
Primary effusion lymphoma (PEL) is a type of body cavity–based lymphoma (BCBL). Most patients with PEL are severely immunocompromised and seropositive for human immunodeficiency virus (HIV). We investigated the distinctive clinicopathologic characteristics of BCBL in a country with low HIV burden.
Materials and Methods
We retrospectively collected data on the clinicopathologic characteristics, treatments, and outcomes of 17 consecutive patients with BCBL at nine institutions in Korea.
Results
Latency-associated nuclear antigen 1 (LANA1) immunostaining indicated that six patients had PEL, six patients had human herpesvirus 8 (HHV8)-unrelated BCBL, and five patients had HHV8-unknown BCBL. The patients with PEL exhibited no evidence of immunodeficiency except for one who was HIV positive. One (20%) and four (80%) patients with PEL and six (100%) and zero (0%) patients with HHV8-unrelated BCBL were positive for CD20 and CD30 expression, respectively. The two patients with PEL (one HIV-positive and one HIV-negative patient) with the lowest proliferation activity as assessed by the Ki-67 labeling index survived for > 1 and > 4 years without chemotherapy, respectively, in contrast to the PEL cases in the literature, which mostly showed a high proliferation index and poor survival.
Conclusion
PEL mostly occurred in ostensibly immunocompetent individuals and had a favorable outcome in Korea. A watchful waiting approach may be applicable for managing HIV-seronegative patients with PEL with a low Ki-67 labeling index. A possible trend was detected among LANA1, CD20, and CD30 expression in BCBL.

Citations

Citations to this article as recorded by

Space-associated lymphomas: review of a heterogeneous group of old and new entities
Judith A Ferry
Diagnostic Histopathology.2024; 30(8): 430. CrossRef
A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients
Julien Calvani, Laurence Gérard, Jehane Fadlallah, Elsa Poullot, Lionel Galicier, Cyrielle Robe, Margaux Garzaro, Remi Bertinchamp, David Boutboul, Wendy Cuccuini, Jean-Michel Cayuela, Philippe Gaulard, Éric Oksenhendler, Véronique Meignin
American Journal of Surgical Pathology.2022; 46(3): 353. CrossRef
A Rapidly Accumulating Effusion in an Immunocompetent Woman
Zein Kattih, Akhilesh Mahajan, Morana Vojnic, Jordan Steinberg, Alyssa Yurovitsky, Jin Ah Kim, Amory Novoselac
Chest.2022; 161(6): e377. CrossRef
Human herpesvirus‐8–positive primary effusion lymphoma in HIV‐negative patients: Single institution case series with a multidisciplinary characterization
Giovanni Rossi, Ilaria Cozzi, Irene Della Starza, Lucia Anna De Novi, Maria Stefania De Propris, Aurelia Gaeta, Luigi Petrucci, Alessandro Pulsoni, Federica Pulvirenti, Valeria Ascoli
Cancer Cytopathology.2021; 129(1): 62. CrossRef
Primary effusion lymphoma in human immune deficiency (HIV)‐negative non‐organ transplant immunocompetent patients
Lisi Yuan, James R. Cook, Tarik M. Elsheikh
Diagnostic Cytopathology.2020; 48(4): 380. CrossRef
Clinicopathologic characteristics and survival of patients with primary effusion lymphoma
Cristian Aguilar, Caddie Laberiano, Brady Beltran, Cecilia Diaz, Alvaro Taype-Rondan, Jorge J. Castillo
Leukemia & Lymphoma.2020; 61(9): 2093. CrossRef

7,011 View
159 Download
6 Web of Science
6 Crossref

Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma: Hansang Lee, Dongryul Oh, Kyungmi Yang, Young Hyeh Ko, Yong Chan Ahn, Won Seog Kim, Seok Jin Kim; Cancer Res Treat. 2019;51(2):547-555. Published online July 10, 2018; DOI: https://doi.org/10.4143/crt.2018.190

Abstract PDF Supplementary Material PubReader ePub

Purpose
Duodenal-type follicular lymphoma (FL) is a rare variant of FL. There is still no consensus on the initial treatment, and clinical features including endoscopic findings are not familiar to most physicians. The objective of this study was to evaluate the outcome of patients who were initially treated with radiation therapy for duodenal-type FL.
Materials and Methods
We retrospectively analyzed 20 patients who were consecutively diagnosed with duodenaltype FL between 2008 and 2017. All patients received radiation therapywith curative intent.
Results
The median age of the patients was 52 years (range, 26 to 66 years), and females were predominant. Most patients (n=18, 90%) had stage I disease, and were diagnosed by a regular health examination in an asymptomatic state. The histological grade was one in 19 patients (95%), and the endoscopic findings were diffuse nodular (n=8), whitish granular (n=8), and mixed pattern (n=4). Radiation therapy was delivered to 17 patients with 24 Gy in 12 fractions, and to three patients with 30.6-36 Gy in 18 fractions. All patients were evaluated with endoscopy for response to radiation therapy, and complete response was achieved in 19 patients (95%). At the time of analysis, all patients survived without any evidence of late toxicities related with radiation therapy.
Conclusion
Taken together, radiation therapy alone could be effective in controlling duodenal lesion. A further study with longer follow-up duration is warranted to confirm our findings.

Citations

Citations to this article as recorded by

Clinical characteristics and outcomes of Brazilian patients with duodenal-type follicular lymphoma: a multicenter retrospective study
Guilherme Duffles, Arthur Braga, Talita Silveira, Yana Novis, Celso Arrais, Luciana Tucunduva, Ana Rita Fonseca, Davimar Borducchi, Pedro Neffa, Fernando Blumm, Marianne de Castro Gonçalves, Frederico Moreira, Fabio Nucci, Eduardo Rego, Vanderson Rocha
Leukemia & Lymphoma.2025; 66(1): 95. CrossRef
Bridging clinicopathologic features and genetics in follicular lymphoma: Towards enhanced diagnostic accuracy and subtype differentiation
Jan Bosch-Schips, Xenia Parisi, Fina Climent, Francisco Vega
Human Pathology.2025; 156: 105676. CrossRef
The Role of Small Bowel Capsule Endoscopy in Determining the Treatment Strategy for Duodenal Follicular Lymphoma: A Single-Center Retrospective Study
Donghoon Kang, Gi-June Min, Tong Yoon Kim, Young-Woo Jeon, Yukyung Cho, Jae Myung Park, Joo Hyun O, Byung-Ock Choi, Gyeongsin Park, Seok-Goo Cho
Diagnostics.2025; 15(2): 193. CrossRef
Recent updates on treatment options for primary follicular lymphoma of the gastrointestinal tract
Masaya Iwamuro, Takehiro Tanaka, Daisuke Ennishi, Motoyuki Otsuka
Expert Review of Gastroenterology & Hepatology.2024; 18(7): 367. CrossRef
Duodenal-type follicular lymphoma: comprehensive insights into disease characteristics and established treatment strategies
Ahmed Alnughmush, Riad El Fakih, Ruah Alyamany, Nasir Bakshi, Saud Alhayli, Mahmoud Aljurf
Current Opinion in Oncology.2024; 36(6): 577. CrossRef
Duodenal Polyposis: An Incidental Finding of Duodenal-Type Follicular Lymphoma
Rachael Hagen, Jasmine Tidwell, Emily Weng, Steven A Goldenberg, Anjiya Shaikh
Cureus.2024;[Epub] CrossRef
Increased Risk of Diabetes after Definitive Radiotherapy in Patients with Indolent Gastroduodenal Lymphoma
Jong Yun Baek, Do Hoon Lim, Dongryul Oh, Heerim Nam, Jae J Kim, Jun Haeng Lee, Byung-Hoon Min, Hyuk Lee
Cancer Research and Treatment.2022; 54(1): 294. CrossRef
Duodenal Follicular Lymphoma: Track or Treat?
M. Varanese, A. Lauro, I. Lattina, D. Tripodi, T. Daralioti, S. Khouzam, I. R. Marino, V. Stigliano, V. D’Andrea, S. Frattaroli, S. Sorrenti
Digestive Diseases and Sciences.2022; 67(5): 1733. CrossRef
Incidentally Found Mucosal Nodularity on the Second Portion of Duodenum
Joo Hyun Lim
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2022; 22(2): 163. CrossRef
Duodenal-type follicular lymphoma more than 10 years after treatment intervention: A retrospective single-center analysis
Makoto Saito, Akio Mori, Shihori Tsukamoto, Takashi Ishio, Emi Yokoyama, Koh Izumiyama, Masanobu Morioka, Takeshi Kondo, Hirokazu Sugino
World Journal of Gastrointestinal Oncology.2022; 14(8): 1552. CrossRef
Linfoma folicular duodenal primario: reporte de caso y revisión de la literatura
Lázaro Antonio Arango Molano, Andrés Sánchez Gil, Ileana Rocío Bautista Parada
Revista colombiana de Gastroenterología.2021; 36(4): 525. CrossRef
What do we know about duodenal‐type follicular lymphoma? From pathological definition to treatment options
Guilherme Duffles Amarante, Graham Collins, Vanderson Rocha
British Journal of Haematology.2020; 188(6): 831. CrossRef
Scientific Advances and the Evolution of Diagnosis, Subclassification and Treatment of Lymphoma
Judith A. Ferry
Archives of Medical Research.2020; 51(8): 749. CrossRef
Development of diffuse large B-cell lymphoma from duodenal type follicular lymphoma: a retrospective study of 23 cases
Masuho Saburi, Yoshiyuki Kondo, Masao Ogata, Yasuhiro Soga, Miyuki Abe, Kuniko Takano, Kazuhiro Kohno, Takayuki Nagai, Toshiyuki Nakayama
International Journal of Hematology.2020; 112(5): 658. CrossRef
Analysis of the response time to involved-field radiotherapy in primary gastrointestinal low-grade B-cell lymphoma
Kyu Hye Choi, Han Hee Lee, Seung-Eun Jung, Kyung-Sin Park, Joo-Hyun O, Young-Woo Jeon, Byung-Ock Choi, Seok-Goo Cho
Radiation Oncology.2020;[Epub] CrossRef

11,989 View
270 Download
13 Web of Science
15 Crossref

Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study: Danbee Kang, Juhee Cho, Im Ryung Kim, Mi Kyung Kim, Won Seog Kim, Seok Jin Kim; Cancer Res Treat. 2018;50(4):1051-1063. Published online November 9, 2017; DOI: https://doi.org/10.4143/crt.2017.207

Abstract PDF Supplementary Material PubReader ePub

Purpose
We evaluated health-related quality of life (HRQOL) in long-term survivors of indolent and aggressive non-Hodgkin lymphoma (NHL).
Materials and Methods
TheHRQOLwas assessed by the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) at diagnosis in NHL patients between 2008 and 2011, and follow-up evaluation was conducted from June 2014 to February 2015 using EORTC QLQ-C30 and the quality of life in cancer survivors (QOL-CS) questionnaire. We used linear mixed models to compare changes in HRQOL between indolent and aggressive NHL over time.
Results
The HRQOL of long-term survivors with aggressive NHL improved to the similar level of indolent NHL during the follow-up survey. However, survivors of NHL were found to fear the probability of relapse and second malignancy, and the degree of fear was not different between survivors with aggressive stage I/II or III/IV NHL (p > 0.05). Furthermore, a half of survivors reported impaired sense of psychosocial well-being regardless of aggressiveness and stage during follow-up survey. More than 65% of survivors thought they did not receive sufficient support from others, and patients who had financial difficulties at diagnosis were more frequently associated with suffering from insufficient support. Impaired physical and cognitive functioning at diagnosis was significantly associated with lack of life purpose in long-term survivors.
Conclusion
The HRQOL of aggressive NHL survivors improved to a similar level to that of indolent NHL. However, the majority of survivors still had fear of relapse, and psychosocial well-being remained unmet needs.

Citations

Citations to this article as recorded by

Attenuated adiponectin, omentin, increased interleukin-6 and tumor necrosis factor-alpha levels with altered cognition and depression in non-Hodgkin lymphoma patients: A case-control study
Meghavi Kathpalia, Pinki Mishra, Afsha Majid, Mohd. Ashif Khan, Anurag Sharma, Dinesh Bhurani, Nidhi
Journal of Neuroimmunology.2024; 392: 578372. CrossRef
Quality of life and late therapy effects in pediatric non‐Hodgkin lymphoma survivors: Insights from a single‐institution study
Azza Ayad, Reham Khedr, Asmaa Hamoda, Nahla Elnabarawy, Elhamy Rifky, Tamer Diab, Eman El Desouky, Leslie Lehmann, Alaa Elhaddad
Pediatric Blood & Cancer.2024;[Epub] CrossRef
Willingness to pay per quality-adjusted life year of Non-Hodgkin Lymphoma patients in Vietnam
Phan Gia Huy, Pham Xuan Dung, Dang The Thap, Nguyen Tran Nhu Y
Tạp Chí Khoa học Trường Đại học Quốc tế Hồng Bàng.2024; : 11. CrossRef
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study
Sohee Park, Ju Hwan Kim, Songhee Kim, Jisu Kang, Seoyoung Moon, Seok Jin Kim, Ju-Young Shin
Blood Cancer Journal.2023;[Epub] CrossRef
Factors associated with long-term functional and psychosocial outcomes in patients with non-Hodgkin lymphoma
Bhasker Amatya, Michael Dickinson , Fary Khan
Journal of Rehabilitation Medicine.2023; 55: jrm004816. CrossRef
Experiences of and preferences for self-management among low grade non-Hodgkin's lymphoma survivors: A qualitative interview study
Nickola D. Pallin, Mairead O'Connor, Alannah Gannon, John Browne, Mary R. Cahill, Derville O'Shea
European Journal of Oncology Nursing.2023; 66: 102378. CrossRef
Factors Affecting Health-Related Quality of Life among Survivors of Non-Hodgkin Lymphoma: A Population-Based Study
Stephane Kroudia Wasse, Morgane Mounier, Emerline Assogba, Cédric Rossi, Johan Adnet, Sophie Gauthier, Stephanie Girard, Kueshivi Midodji Atsou, Tienhan Sandrine Dabakuyo-Yonli, Marc Maynadie
Cancers.2023; 15(15): 3885. CrossRef
Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study
Leo I. Gordon, Fei Fei Liu, Julia Braverman, Daanish Hoda, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C. Hildebrandt, Lily Peng, Shien Guo, Ling Shi, Alison Sehgal
Haematologica.2023; 109(3): 857. CrossRef
Quality of life and fear of cancer recurrence in patients and survivors of non-Hodgkin lymphoma
Susan Ellis, Rhonda F. Brown, Einar B. Thorsteinsson, Kenneth I. Pakenham, Colin Perrott
Psychology, Health & Medicine.2022; 27(8): 1649. CrossRef
Pre‐treatment health‐related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA‐BERIT) experience
Åsa Lindberg, Christian Winther Eskelund, Alexandra Albertsson‐Lindblad, Arne Kolstad, Anna Laurell, Riikka Räty, Kirsten Grønbæk, Christian Hartmann Geisler, Mats Jerkeman
Hematological Oncology.2022; 40(1): 23. CrossRef
Treatment Outcomes and Its Associated Factors Among Adult Patients with Selected Solid Malignancies at Kenyatta National Hospital: A Hospital-Based Prospective Cohort Study
Amsalu Degu, Ermias Mergia Terefe, Eliab Seroney Some, Gobezie T Tegegne
Cancer Management and Research.2022; Volume 14: 1525. CrossRef
Living with or beyond lymphoma: A rapid review of the unmet needs of lymphoma survivors
Vanessa Boland, Amanda Drury, Greg Sheaf, Anne‐Marie Brady
Psycho-Oncology.2022; 31(7): 1076. CrossRef
The forgotten survivor: A comprehensive review on Non‐Hodgkin lymphoma survivorship
Mohamad S. Alabdaljabar, Urshila Durani, Carrie A. Thompson, Louis S. Constine, Shahrukh K. Hashmi
American Journal of Hematology.2022; 97(12): 1627. CrossRef
Unmet Needs and Quality of Life of Colorectal Cancer Survivors Immediately after Treatment Ends and 5 Years
Hyedan Kim, Eunsook Wi, Mi Hwa Jang, Sung Hee Jo, Hye Kyung Kim
Asian Oncology Nursing.2022; 22(3): 145. CrossRef
Trajectories of symptom severity predicts quality of life change in newly diagnosis lymphoma survivors: An initial study
Chih‐Jung Wu, Yu‐Chi Chen, Li‐Yuan Bai, Tzeon‐Jye Chiou, Kuan‐Chia Lin, Ya‐Jung Wang
European Journal of Cancer Care.2022;[Epub] CrossRef
Exploring health-related quality of life among non-Hodgkin’s lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand
Pichitra Lekdamrongkul, Kanaungnit Pongthavornkamol, Alex Molassiotis, Aurawamon Sriyuktasuth, Noppadol Siritanaratkul, Natkamol Chansatitporn
Supportive Care in Cancer.2021; 29(11): 6511. CrossRef
Experiences of patients with lung cancer receiving concurrent chemo-radiotherapy
Choi Eunsook, Park Sunhee
Clinical Journal of Nursing Care and Practice.2021; 5(1): 015. CrossRef
Coping strategies among patients with malignant lymphoma– a qualitative study from the perspectives of Swedish patients
Stinne Glasdam, Charlotta Bjerström, Cecilia Engberg de Carvalho
European Journal of Oncology Nursing.2020; 44: 101693. CrossRef
Impact of fear of cancer recurrence on survival among lymphoma patients
Seok Jin Kim, Danbee Kang, Im Ryung Kim, Sang Eun Yoon, Won Seog Kim, Phyllis N. Butow, Eliseo Guallar, Juhee Cho
Psycho-Oncology.2020; 29(2): 364. CrossRef
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
Andrew Davies, Peter Trask, Judit Demeter, Axel Florschütz, Mathias Hänel, Tomohiro Kinoshita, Ruth Pettengell, Hang Quach, Stephen Robinson, Shalal Sadullah, Juan-Manuel Sancho, Miklos Udvardy, Mathias Witzens-Harig, Andrea Knapp, Wenxin Liu
Annals of Hematology.2020; 99(12): 2837. CrossRef
Quality of Life and Impact of Cancer: Differences in Rural and Nonrural Non‐Hodgkin's Lymphoma Survivors
Devon Noonan, Matthew LeBlanc, Cherie Conley, Habtamu Benecha, Ashley Leak‐Bryant, Kellen Peter, Sheryl Zimmerman, Deborah Mayer, Sophia Smith
The Journal of Rural Health.2020; 36(4): 536. CrossRef
Semen quality in non-Hodgkin lymphoma survivors: a monocentric retrospective study
Francesco Pallotti, Marianna Pelloni, Fabiana Faja, Silvia Di Chiano, Alice Di Rocco, Andrea Lenzi, Francesco Lombardo, Donatella Paoli
Human Reproduction.2020;[Epub] CrossRef
Prognostic Value of Post-diagnosis Health-Related Quality of Life for Overall Survival in Breast Cancer: Findings from a 10-Year Prospective Cohort in Korea
Tran Thi Xuan Mai, Jin Hyuk Choi, Myung Kyung Lee, Yoon Jung Chang, So-Youn Jung, Hyunsoon Cho, Eun Sook Lee
Cancer Research and Treatment.2019; 51(4): 1600. CrossRef

17,620 View
427 Download
21 Web of Science
23 Crossref

Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell Lymphoma: Ga-In Lee, Dongryul Oh, Won Seog Kim, Seok Jin Kim, Young Hyeh Ko, Kyung In Woo, Yoon-Duck Kim, Yong Chan Ahn; Cancer Res Treat. 2018;50(2):575-581. Published online June 16, 2017; DOI: https://doi.org/10.4143/crt.2017.182

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to evaluate the clinical features and the long-term outcomes of primary conjunctival marginal zone B-cell lymphoma (MZBCL) patients who were treated with radiation therapy (RT).
Materials and Methods
Retrospective data of 79 patients with 121 primary conjunctival MZBCL lesions were collected from January 1, 2001 till June 30, 2014. All lesions were treated by local RT (26 Gy) with patient-specific customized lens-shielding device.
Results
The current Korean patients’ cohort showed younger median age at diagnosis (38 years), great female preponderance (78.5%) and more frequent bilateral involvement (53.2%) than the previous studies. Following 26 Gy’s RT, excellent clinical outcomes were achieved: 5-year rates of overall survival, local relapse-free survival, and contralateral relapse-free survival were 100%, 98.1%, and 91.5%, respectively. Two patients (2.5%) developed local relapse and five (6.3%) developed relapse at initially uninvolved contralateral conjunctiva with median interval of 52.9 months, and late adverse events of grade 2 and 3 occurred in seven (8.8%) and two (2.5%) patients, respectively.
Conclusion
26 Gy’s RT was highly effective and safe, with the use of lens-shielding device, in treating patients with primary conjunctival MZBCL.

Citations

Citations to this article as recorded by

Deintensification of radiation dose to 20 Gy for conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma
Jaeha Lee, Si Yeol Song, Young Seob Shin, Sung-Woo Kim, Ye Jin Yoo, Ji Hyeon Joo, Ho-Seok Sa, Dok Hyun Yoon, Sang-wook Lee
Leukemia & Lymphoma.2025; : 1. CrossRef
Iatrogenic Ocular Surface Complications After Surgery for Ocular and Adnexal Tumors
Maria Angela Romeo, Andrea Taloni, Massimiliano Borselli, Alessandra Di Maria, Alessandra Mancini, Vincenzo Mollace, Giovanna Carnovale-Scalzo, Vincenzo Scorcia, Giuseppe Giannaccare
Cancers.2025; 17(9): 1384. CrossRef
Clinicopathologic features of conjunctival MALT lymphomas refractory to radiation therapy
Yuka Suimon, Satoru Kase, Rumiko Kinoshita, Susumu Ishida
Canadian Journal of Ophthalmology.2024; 59(5): e501. CrossRef
Long‐term outcomes of patients with conjunctival extranodal marginal zone lymphoma
Eduardo Edelman Saul, Juan Pablo Alderuccio, Isildinha M. Reis, Wei Zhao, Sunil G. Iyer, Gregor Rodriguez, Amrita Desai, Jennifer R. Chapman, David T. Tse, Arnold M. Markoe, Derek M. Isrow, Izidore S. Lossos
American Journal of Hematology.2023; 98(1): 148. CrossRef
Conjunctival Lymphoma
Lindsay A. McGrath, David A. Ryan, Sunil K. Warrier, Sarah E. Coupland, William J. Glasson
Eye.2023; 37(5): 837. CrossRef
Long‐term survival outcomes of patients with primary ocular adnexal MALT lymphoma: A large single‐center cohort study
Yuanzheng Liang, Rui‐ying Fu, Xue‐lin Liu, Xin‐di Liu, Ying‐shi Piao, Jian‐min Ma, Liang Wang
Cancer Medicine.2023; 12(3): 2514. CrossRef
Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa‐associated lymphoid tissue lymphoma: A retrospective study
Kentaro Mizuhara, Tsutomu Kobayashi, Mitsushige Nakao, Ryoichi Takahashi, Hiroto Kaneko, Kazuho Shimura, Koichi Hirakawa, Nobuhiko Uoshima, Katsuya Wada, Eri Kawata, Reiko Isa, Takahiro Fujino, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Akiko Yoneda
Cancer Medicine.2023; 12(3): 3134. CrossRef
Apigenin and Exposure to Low Dose Gamma Radiation Ameliorate Acetic Acid-Induced Ulcerative Colitis in Rats
Eman E. Shibrya, Rasha R. Rashed, Mai A. Abd El Fattah, Mona A. El-Ghazaly, Sanaa A. Kenawy
Dose-Response.2023;[Epub] CrossRef
Ultra-low-dose radiation treatment for early-stage ocular adnexal MALT lymphoma
Min Joung Lee, Me Yeon Lee, Ji-Young Choe, Se Hyun Choi, Hyo Jung Kim
European Journal of Ophthalmology.2022; 32(5): 3092. CrossRef
Ultra-low dose external beam radiotherapy for presumed choroidal lymphoma: a case report
Jeremy P. M. Flanagan, Michael Ng, Awet Z. Kibrom, Robin J. A. Filshie, Richard J. Stawell, Roderick F. O’Day
Journal of Ophthalmic Inflammation and Infection.2022;[Epub] CrossRef
One Case of Conjunctival MALT Lymphoma and Literature Review
旭霞李
Advances in Clinical Medicine.2022; 12(08): 7586. CrossRef
Ocular surface complications of local anticancer drugs for treatment of ocular tumors
Jayoon Moon, Se Hyun Choi, Min Joung Lee, Dong Hyun Jo, Un Chul Park, Sun-Ok Yoon, Se Joon Woo, Joo Youn Oh
The Ocular Surface.2021; 19: 16. CrossRef
Ocular Oncology—Primary and Metastatic Malignancies
Basil K. Williams, Maura Di Nicola
Medical Clinics of North America.2021; 105(3): 531. CrossRef
Iatrogenic Ocular Surface Diseases Occurring during and/or after Different Treatments for Ocular Tumours
Giuseppe Giannaccare, Federico Bernabei, Martina Angi, Marco Pellegrini, Antonio Maestri, Vito Romano, Vincenzo Scorcia, Pierre-Räphael Rothschild
Cancers.2021; 13(8): 1933. CrossRef
Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients
Khaled Elsayad, Gabriele Reinartz, Michael Oertel, Stephan Rehn, Jens Eismann, Sergiu Scobioala, Hendrik Berssenbrügge, Nicole Eter, Carsten Weishaupt, Hartmut H. Schmidt, Birte Friedrichs, Inga Grünewald, Wolfgang Hartmann, Georg Lenz, Eva Wardelmann, No
Strahlentherapie und Onkologie.2020; 196(2): 117. CrossRef
Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum
Andrés J. M. Ferreri, Marianna Sassone, Elisabetta Miserocchi, Silvia Govi, Caterina Cecchetti, Matteo E. Corti, Silvia Mappa, Luca Arcaini, Francesco Zaja, Giuseppe Todeschini, Donato Mannina, Teresa Calimeri, Salvatore Perrone, Maurilio Ponzoni, Giulio
Blood Advances.2020; 4(6): 1013. CrossRef
Patterns of care for orbital marginal zone B‐cell lymphoma of mucosa‐associated lymphoid tissue in Korea throughout 2016: Results from a multicenter cross‐sectional cohort study (KROG 16–19)
Jeongshim Lee, Dongryul Oh, Byung Ock Choi, Keun‐Yong Eom, Jong Hoon Lee, Jung Hoon Kim, Sang Wook Lee, Yang Kwon Suh, Chang‐Ok Suh
Asia-Pacific Journal of Clinical Oncology.2019; 15(6): 358. CrossRef
Classification, diagnosis, and management of conjunctival lymphoma
Rebecca E. Tanenbaum, Anat Galor, Sander R. Dubovy, Carol L. Karp
Eye and Vision.2019;[Epub] CrossRef
Necrotizing Fasciitis: Low-Dose Radiotherapy as a Potential Adjunct Treatment
Gaurav Dhawan, Rachna Kapoor, Asha Dhamija, Ravinder Singh, Bharat Monga, Edward J. Calabrese
Dose-Response.2019; 17(3): 155932581987175. CrossRef
Health Impacts of Low-Dose Ionizing Radiation: Current Scientific Debates and Regulatory Issues
Alexander Vaiserman, Alexander Koliada, Oksana Zabuga, Yehoshua Socol
Dose-Response.2018;[Epub] CrossRef

15,681 View
250 Download
20 Web of Science
20 Crossref

Validation of the Korean Version of the Quality of Life–Cancer Survivors (QOL-CS-K) Questionnaire in Lymphoma Survivors: Juhee Cho, Danbee Kang, Im Ryung Kim, Won Seog Kim, Betty Ferrell, Seok Jin Kim; Cancer Res Treat. 2018;50(1):204-211. Published online March 30, 2017; DOI: https://doi.org/10.4143/crt.2017.091

Abstract PDF Supplementary Material PubReader ePub

Purpose
The objective of this study was to validate the Korean version of the Quality of Life–Cancer Survivors (QOL-CS-K) in a sample of lymphoma survivors.
Materials and Methods
We conducted a cross-sectional survey of lymphoma survivors who had survived for at least 24 months since diagnosis. Participants were recruited at the outpatient clinics and at a hospital event in a tertiary hospital in Seoul, Korea. Survivors were asked to complete the QOLCS-K and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) questionnaires. To determine test-retest reliability, a second questionnaire was sent to participants who completed the first questionnaire adequately. Exploratory factor analysis and Pearson’s correlations were used for evaluating reliability and validity of the QOL-CS-K.
Results
Among 257 survivors, 245 (95.3%) completed all questionnaires and had no missing data. The mean age of study participants was 52.2 years, 54.9% were men, and the mean time since diagnosis was 4.0±1.6 years. The Cronbach’s α for the overall QOL-CS-K was 0.90, and the α coefficients for each subscale ranged from 0.73 to 0.83. The test and retest reliability was 0.88. Moderate correlations were found between comparable subscales of the QOL-CS-K and subscales of the EORTC QLQ-C30 (r=0.51-0.55) except for the spiritual well-being subscale of the QOL-CS-K, which did not correlate with any of the EORTC QLQ-C30 subscales (–0.08 to 0.16).
Conclusion
The QOL-CS-K is a reliable and valid scale for measuring the QOL in long-term lymphoma survivors.

Citations

Citations to this article as recorded by

Korean patients with hereditary cancer: a prospective multicentre cohort study protocol exploring psychosocial and health outcomes
Jun-Kyu Kim, Mi-Ae Jang, Jong Eun Park, Dongju Won, Jung-Sook Ha, Kyoung-Bo Kim, Boyoung Park, Sun-Young Kong
BMJ Open.2025; 15(2): e093905. CrossRef
Unmet Needs Mediate the Impact of Fear of Cancer Recurrence on Screening Participation Among Cancer Survivors: A Cross-Sectional Study
Mi-Lee Kim, Yeol Kim, Yu-Ri Choe
Healthcare.2025; 13(10): 1184. CrossRef
Measuring patient‐reported distress from breast magnetic resonance imaging: Development and validation of the MRI‐related distress scale (MRI‐DS)
Danbee Kang, Sooyeon Kim, Jiyoon Han, Youngha Kim, Juhee Cho, Jeong Eon Lee, Eun Sook Ko
Cancer Medicine.2024;[Epub] CrossRef
Quality of life patient/cancer survivor version in Chinese cancer survivors: A validation study
Hai-Ying Wang, Stephen Wai Hang Kwok, Xian-Liang Liu, Tao Wang, Daniel Bressington, Yushan Shen, Qing Zhang, Hou-Qiang Huang, Jing-Yu Tan
Asia-Pacific Journal of Oncology Nursing.2023; 10(8): 100255. CrossRef
Analysis of etiological factors of nursing diagnosis of impaired comfort in children and adolescents with cancer
Tânia Alteniza Leandro, Viviane Martins da Silva, Marcos Venícios de Oliveira Lopes, Nayana Maria Gomes de Souza, Kiarelle Lourenço Penaforte, Emanuela Aparecida Teixeira Gueiros, Marisa Nascimento de Oliveira
Journal of Advanced Nursing.2023; 79(10): 3913. CrossRef
Prediction Model for Postoperative Quality of Life Among Breast Cancer Survivors Along the Survivorship Trajectory From Pretreatment to 5 Years: Machine Learning–Based Analysis
Danbee Kang, Hyunsoo Kim, Juhee Cho, Zero Kim, Myungjin Chung, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Jai Min Ryu, Se Kyung Lee
JMIR Public Health and Surveillance.2023; 9: e45212. CrossRef
The early predictive value of frailty for health-related quality of life among elderly patients with cancer receiving curative chemotherapy
Yi-Cheng Hu, Shih-Ying Chen, Wen-Chi Chou, Jen-Shi Chen, Li-Chueh Weng, Pei-Kwei Tsay, Woung-Ru Tang, Chong-Chi Chiu
PLOS ONE.2023; 18(8): e0287320. CrossRef
The effect of web‐based intervention programs on self‐management and symptom management in patients with lymphoma: A systematic review of randomized controlled trials
Merve Gozde Sezgin, Hicran Bektas
Japan Journal of Nursing Science.2022;[Epub] CrossRef
Factors affecting the quality of life of gastric cancer survivors
Jahyun Choi, Sanghee Kim, Mona Choi, Woo Jin Hyung
Supportive Care in Cancer.2022; 30(4): 3215. CrossRef
The effect of decision support systems on pain in patients with cancer: A systematic review and meta‐analysis of randomized controlled trials
Merve Gozde Sezgin, Hicran Bektas
Journal of Nursing Scholarship.2022; 54(5): 578. CrossRef
Impact of objective financial burden and subjective financial distress on spiritual well-being and quality of life among working-age cancer survivors
Danbee Kang, Ka Ryeong Bae, Jihyun Lim, Nayeon Kim, Sungkeun Shim, Sun Seog Kweon, Hwa Jeong Seo, Juhee Cho
Supportive Care in Cancer.2022; 30(6): 4917. CrossRef
Feasibility and potential effects of breathing exercise for chronic pain management in breast cancer survivors: study protocol of a phase II randomised controlled trial
Haiying Wang, Jing-Yu (Benjamin) Tan, Tao Wang, Xian-Liang Liu, Daniel Bressington, Si-Lin Zheng, Hou-Qiang Huang
BMJ Open.2022; 12(12): e064358. CrossRef
Health-related quality of life after transoral robotic thyroidectomy in papillary thyroid carcinoma
Chang Myeon Song, Hyang Sook Bang, Hyung Gu Kim, Hae Jin Park, Kyung Tae
Surgery.2021; 170(1): 99. CrossRef
Impact of fear of cancer recurrence on survival among lymphoma patients
Seok Jin Kim, Danbee Kang, Im Ryung Kim, Sang Eun Yoon, Won Seog Kim, Phyllis N. Butow, Eliseo Guallar, Juhee Cho
Psycho-Oncology.2020; 29(2): 364. CrossRef
A return-to-work intervention protocol directed at cancer patients (self-assessment, tailored information & lifestyle management for returning to work among cancer patients, START): A multi-center, randomized controlled trial
Ka Ryeong Bae, Danbee Kang, Jae Yoon Yi, Yeojin Ahn, Im-Ryung Kim, Sun-Seog Kweon, Jin Seok Ahn, Seok Jin Nam, Young Mog Shim, Mison Chun, Jaesung Heo, Juhee Cho
Contemporary Clinical Trials Communications.2020; 19: 100633. CrossRef
Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study
Danbee Kang, Juhee Cho, Im Ryung Kim, Mi Kyung Kim, Won Seog Kim, Seok Jin Kim
Cancer Research and Treatment.2018; 50(4): 1051. CrossRef

9,799 View
272 Download
16 Web of Science
16 Crossref

Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma: Chi Hoon Maeng, Young Hyeh Ko, Do Hoon Lim, Eun Suk Kang, Joon Young Choi, Won Seog Kim, Seok Jin Kim; Cancer Res Treat. 2017;49(1):92-103. Published online May 9, 2016; DOI: https://doi.org/10.4143/crt.2015.476

Abstract PDF PubReader ePub

Purpose
This retrospective study was conducted for comparison of survival outcomes and toxicities of autologous stem cell transplantation (ASCT) based on the use of total body irradiation (TBI) as a part of the conditioning regimen in patients with mature T- and natural killer (NK)-cell lymphomas.
Materials and Methods
Patients who underwent ASCT in the upfront or salvage setting between January 2000 and December 2013 were analyzed. Patients were dichotomized according to the TBI group (n=38) and non-TBI group (n=60) based on the type of conditioning regimen for ASCT.
Results
Patients with responsive disease underwent upfront ASCT (TBI, n=16; non-TBI, n=29) whereas patients with refractory disease (TBI, n=9; non-TBI, n=12) or relapsed disease (TBI, n=13; non-TBI, n=19) underwent ASCT after salvage treatment. Hematologic and non-hematologic toxicities were manageable, and the median cumulative toxicity score according to Seattle criteria was estimated as 2 (range, 0 to 7) in both groups. No significant difference in 100-day mortality was observed between the TBI (13%, 5/38) and non-TBI (12%, 12/60) groups, and most deaths were related to disease progression. There was no difference in overall and progression-free survival; however, the TBI group showed a trend of better survival in upfront and salvage ASCT than the non-TBI group. However, patients with refractory disease showed the worst outcome regardless of the use of TBI. Patients who showed complete response before ASCT showed better progression-free survival than thosewho showed partial response.
Conclusion
TBI could be used as an effective part of conditioning for ASCT in patients with mature T- and NK-cell lymphomas.

Citations

Citations to this article as recorded by

Whole body irradiation with intensity-modulated helical tomotherapy prior to haematopoietic stem cell transplantation: analysis of organs at risk by dose and its effect on blood kinetics
Mümtaz Köksal, Jonathan Baumert, Danny Jazmati, Felix Schoroth, Stephan Garbe, David Koch, Davide Scafa, Gustavo R. Sarria, Christina Leitzen, Gregor Massoth, Achilles Delis, Annkristin Heine, Tobias Holderried, Peter Brossart, Thomas Müdder, Leonard C. S
Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7007. CrossRef
The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation
Hao Wang, Kristin N. Berger, Elizabeth L. Miller, Wei Fu, Larisa Broglie, Frederick D. Goldman, Heiko Konig, Su Jin Lim, Arthur S. Berg, Julie-An Talano, Melanie A. Comito, Sherif S. Farag, Jeffrey J. Pu
Therapeutic Advances in Hematology.2023;[Epub] CrossRef
Helical versus static approaches to delivering tomotherapy to the junctional target for patients taller than 135 cm undergoing total body irradiation
Mümtaz Köksal, Jonathan Baumert, Felix Schoroth, Thomas Müdder, Davide Scafa, David Koch, Christina Leitzen, Gustavo R. Sarria, Leonard C. Schmeel, Frank A. Giordano
European Journal of Medical Research.2022;[Epub] CrossRef
National survey of myeloablative total body irradiation prior to hematopoietic stem cell transplantation in Japan: survey of the Japanese Radiation Oncology Study Group (JROSG)
Naoya Ishibashi, Toshinori Soejima, Hiroki Kawaguchi, Takeshi Akiba, Masatoshi Hasegawa, Kouichi Isobe, Hitoshi Ito, Michiko Imai, Yasuo Ejima, Masaharu Hata, Keisuke Sasai, Emiko Shimoda, Toshiya Maebayashi, Masahiko Oguchi, Tetsuo Akimoto
Journal of Radiation Research.2018; 59(4): 477. CrossRef

10,396 View
189 Download
4 Web of Science
4 Crossref

Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism: Sung Hee Lim, Sook-young Woo, Seonwoo Kim, Young Hyeh Ko, Won Seog Kim, Seok Jin Kim; Cancer Res Treat. 2016;48(1):312-321. Published online March 2, 2015; DOI: https://doi.org/10.4143/crt.2014.266

Abstract PDF PubReader ePub

Purpose
The risk factors for venous thromboembolism (VTE) in diffuse large B-cell lymphoma (DLBCL) are not clear although thrombosis can be associated with host status, tumor burden, and inflammatory activity. We assessed the effect of those factors on VTE in a cross-sectional study of patients enrolled in a prospective cohort study. Materials and Methods We analyzed the occurrence of VTE in 322 patients with newly diagnosed DLBCL who received rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) between 2008 and 2011. Serum levels of inflammatory cytokines were measured from serum samples archived at diagnosis.
Results
With a median follow-up duration of 41.9 months, VTE was documented in 34 patients (10.6%). A comparison of baseline characteristics indicated the group with VTE had higher percentage of old age, stage III/IV and extranodal involvements than the group without VTE (p < 0.05). Thus, the International Prognostic Index was significantly associated with VTE, but the Khorana score was not. A univariate competing risk factor analysis for VTE revealed that increased levels of inflammatory cytokines such as interleukin (IL)-6 and IL-10 were also associated with VTE (p < 0.05) in addition to host and tumor burden. However, a multivariate analysis showed that two host factors including age (≥ 60 years) and poor performance were independent risk factors for VTE. Conclusion Among potential risk factors for VTE including tumor burden and inflammatory activity, age and performance status had a strong impact on the occurrence of VTE in patients with DLBCL who received R-CHOP.

Citations

Citations to this article as recorded by

Thromboinflammatory Biomarkers in Lymphomas: Linking Inflammation to Thrombosis Risk
Emilija Živković, Olivera Mitrović-Ajtić, Tijana Subotički, Jelena Ivanović, Vladimir Otašević, Dragoslava Đikić, Miloš Diklić, Milica Vukotić, Teodora Dragojević, Dejana Stanisavljević, Darko Antić, Vladan P. Čokić
International Journal of Molecular Sciences.2025; 26(5): 2058. CrossRef
Assessment and prognostic significance of a serum cytokine panel in diffuse large B‑cell lymphoma
Shufang Xie, Lifen Zhu, Lei Wang, Shibing Wang, Xiangmin Tong, Wanmao Ni
Oncology Letters.2024;[Epub] CrossRef
Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma
Irene Sánchez Prieto, Isabel Gutiérrez Jomarrón, Celia Martínez Vázquez, Pedro Rodríguez Barquero, Paula Gili Herreros, Julio García-Suárez
Journal of Thrombosis and Thrombolysis.2024; 57(6): 984. CrossRef
Thrombosis risk prediction in lymphoma patients: A multi‐institutional, retrospective model development and validation study
Shengling Ma, Jennifer La, Kaitlin N. Swinnerton, Danielle Guffey, Raka Bandyo, Giordana De Las Pozas, Katy Hanzelka, Xiangjun Xiao, Cristhiam M. Rojas‐Hernandez, Christopher I. Amos, Vipul Chitalia, Katya Ravid, Kelly W. Merriman, Christopher R. Flowers,
American Journal of Hematology.2024; 99(7): 1230. CrossRef
Cancer and thrombosis—platelets and anti-platelet drugs—
Kenji YOKOYAMA
Japanese Journal of Thrombosis and Hemostasis.2023; 34(5): 549. CrossRef
Incidence of venous thromboembolism and predictive ability of age-adjusted international prognostic index for prediction of venous thromboembolism in Asian patients with diffuse large B-cell lymphoma
Nonthakorn Hantrakun, Phichayut Phinyo, Adisak Tantiworawit, Ekarat Rattarittamrong, Chatree Chai-Adisaksopha, Thanawat Rattanathammethee, Sasinee Hantrakool, Pokpong Piriyakhuntorn, Teerachat Punnachet, Piangrawee Niprapan, Lalita Norasetthada
Journal of Thrombosis and Thrombolysis.2023; 57(3): 473. CrossRef
Incidence and Risk Factors of Venous Thromboembolism Following Hepatectomy for Colorectal Metastases: A Population‐Based Retrospective Cohort Study
Nader Hanna, Susan B. Brogly, Xuejiao Shelly Wei, Christopher M. Booth, Sulaiman Nanji
World Journal of Surgery.2022; 46(1): 180. CrossRef
Venous‐thromboembolism and associated health care utilization in elderly patients with diffuse large B cell lymphoma
Radhika Gangaraju, Elizabeth S. Davis, Smita Bhatia, Kelly M. Kenzik
Cancer.2022; 128(12): 2348. CrossRef
Issue of predicting the risk of thromboembolic complications in patients with lymphoproliferative diseases
S. V. Ignatiev, A. V. Lyanguzov, E. S. Fokina, N. A. Zorina, K. A. Vorobiev
Oncohematology.2022; 17(2): 134. CrossRef
Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study
Maja Bech Juul, Jelena Jelicic, Pavithra Laxsen Anru, Henriette Engberg, Pernille Hammershøj Jensen, Helene Bjørg Kristensen, Joachim Baech, Michael Roost Clausen, Anne Ortved Gang, Lars Munksgaard, Tarec Christoffer El-Galaly, Henrik Frederiksen, Thomas
Leukemia & Lymphoma.2022; 63(9): 2074. CrossRef
Takotsubo Syndrome (TTS) in Onco-Hematologic Patients: Retrospective Analysis and Focus on the Correlation or Not With Anticancer Drugs. Case Reports and Review of the Literature
Manlio Monti, Pietro Cortesi, Roberto Vespignani, Ilaria Bronico, Chiara Gallio, Michele Flospergher, Laura Matteucci, Giovanni Luca Frassineti
Frontiers in Oncology.2022;[Epub] CrossRef
Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis
Silvia García Adrián, Adán Rodríguez González, Eva Martínez de Castro, Vanessa Pachón Olmos, Laura Ortega Morán, Purificación Martínez del Prado, Mercedes Salgado Fernández, José David Cumplido Burón, Ignacio García Escobar, Joaquina Martínez Galán, Ana I
European Journal of Internal Medicine.2022; 105: 30. CrossRef
Venous thromboembolic events in T-cell lymphoma patients: Incidence, risk factors and clinical features
Yingxia Lan, Jinqiu Guan, Jia Zhu, Juan Wang, Mengzhen Li, Chengtao Sun, Feifei Sun, Junting Huang, Suying Lu, Yizhuo Zhang
Leukemia Research.2021; 103: 106537. CrossRef
Predicting the Incidence of Venous Thromboembolism Using the Khorana Score: A Literature Review
Akari Nishimura, Yoshiaki Ikeda
YAKUGAKU ZASSHI.2021; 141(4): 611. CrossRef
The Application of the ThroLy Risk Assessment Model to Predict Venous Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma
Hikmat Abdel-Razeq, Mohammad Ma’koseh, Asem Mansour, Rayan Bater, Rula Amarin, Alaa Abufara, Khalid Halahleh, Mohammad Manassra, Mohammad Alrwashdeh, Mohammad Almomani, Mais Zmaily
Clinical and Applied Thrombosis/Hemostasis.2021;[Epub] CrossRef
Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH
J. R. Gonzalez-Porras, J. Mateo, V. Gonzalez-Calle, P. Marco, V. Garcia-Gutierrez, J. C. Reverter, R. Lecumberri
Clinical and Translational Oncology.2021; 24(5): 770. CrossRef
The Incidence of Venous Thromboembolism and Impact on Survival in Hodgkin Lymphoma
Onur Kirkizlar, Tugcan Alp Kirkizlar, Elif Gulsum Umit, Ismail Asker, Mehmet Baysal, Volkan Bas, Sedanur Karaman Gulsaran, Ufuk Demirci, Ahmet Muzaffer Demir
Clinical Lymphoma Myeloma and Leukemia.2020; 20(8): 542. CrossRef
Prediction of survival in non-Hodgkin lymphoma based on markers of systemic inflammation, anemia, hypercoagulability, dyslipidemia, and Eastern Cooperative Oncology Group performance status
Ivan Dzis, Oleksandra Tomashevska, Yevhen Dzis, Zoryana Korytko
Acta Haematologica Polonica.2020; 51(1): 34. CrossRef
Mechanisms and biomarkers of cancer-associated thrombosis
Ann S. Kim, Alok A. Khorana, Keith R. McCrae
Translational Research.2020; 225: 33. CrossRef
Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis
Stefan Hohaus, Francesca Bartolomei, Annarosa Cuccaro, Elena Maiolo, Eleonora Alma, Francesco D’Alò, Silvia Bellesi, Elena Rossi, Valerio De Stefano
Cancers.2020; 12(5): 1291. CrossRef
Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis
Knut A. Mosevoll, Silje Johansen, Øystein Wendelbo, Ina Nepstad, Øystein Bruserud, Håkon Reikvam
Frontiers in Medicine.2018;[Epub] CrossRef
Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice
Joanna Rupa‐Matysek, Katarzyna Brzeźniakiewicz‐Janus, Lidia Gil, Zbigniew Krasiński, Mieczysław Komarnicki
Cancer Medicine.2018; 7(7): 2868. CrossRef
Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma
Joanna Rupa-Matysek, Lidia Gil, Marta Barańska, Dominik Dytfeld, Mieczysław Komarnicki
Oncotarget.2018; 9(30): 21190. CrossRef
Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B‐cell lymphoma
Joanna Rupa‐Matysek, Lidia Gil, Renata Kroll‐Balcerzak, Marta Barańska, Mieczysław Komarnicki
Hematological Oncology.2017; 35(4): 456. CrossRef
Risk Assessment for Venous Thromboembolism in Chemotherapy-Treated Ambulatory Cancer Patients
Patrizia Ferroni, Fabio Massimo Zanzotto, Noemi Scarpato, Silvia Riondino, Umberto Nanni, Mario Roselli, Fiorella Guadagni
Medical Decision Making.2017; 37(2): 234. CrossRef
Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma
Ina Hornemann Borg, Mette Dahl Bendtsen, Martin Bøgsted, Jakob Madsen, Marianne Tang Severinsen
Leukemia & Lymphoma.2016; 57(12): 2771. CrossRef
Risk of thromboembolism with lymphoma: myth or reality?
Kate L. Burbury, Marliese Alexander, David A. Westerman
Leukemia & Lymphoma.2016; 57(12): 2736. CrossRef

12,788 View
104 Download
26 Web of Science
27 Crossref

Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis: Silvia Park, Cheol-In Kang, Doo Ryeon Chung, Kyong Ran Peck, Won Seog Kim, Seok Jin Kim; Cancer Res Treat. 2015;47(3):448-457. Published online November 3, 2014; DOI: https://doi.org/10.4143/crt.2014.034

Abstract PDF PubReader ePub

Purpose
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard chemotherapy in diffuse large B-cell lymphoma (DLBCL) patients. Although febrile neutropenia (FN) is the major toxicity of this regimen, non-neutropenic fever (NNF) becomes an emerging issue. Materials and Methods We analyzed clinical features and outcomes of febrile complications from 397 patients with newly diagnosed DLBCL who were registered in the prospective cohort study. They had completed R-CHOP between September 2008 and January 2013. Results Thirty-nine patients (9.8%) had NNF whereas 160 patients (40.3%) had FN. Among them, 24 patients (6.0%) had both during their treatment. Compared to frequent occurrence of initial FN after the first cycle (> 50% of total events), more than 80% of NNF cases occurred after the third cycle. Interstitial pneumonitis comprised the highest proportion of NNF cases (54.8%), although the causative organism was not identified in the majority of cases. Thus, pathogen was identified in a limited number of patients (n=9), and Pneumocystis jiroveci pneumonia (PJP) was the most common. Considering that interstitial pneumonitis without documented pathogen could be clinically diagnosed with PJP, the overall rate of PJP including probable cases was 4.5% (18 cases from 397 patients). The NNF-related mortality rate was 10.3% (four deaths from 39 patients with NNF) while the FN-related mortality rate was only 1.3%. Conclusion NNF was observed with incidence of 10% during R-CHOP treatment, and showed different clinical manifestations with respect to the time of initial episode and causes.

Citations

Citations to this article as recorded by

Incidence and risk factors of severe infections in diffuse large B-cell lymphoma patients undergoing immunochemotherapy
Haiqiu Zhao, Rong Su, Jie Luo, Lin Liu
Annals of Hematology.2025; 104(5): 2869. CrossRef
Interstitial lung disease presents with varying characteristics in patients with non-Hodgkin lymphoma undergoing rituximab-containing therapies
Wailong Zou, Jia Zhang, Yulin Li, Zhe Zhang, Rui Yang, Yaxin Yan, Weihua Zhu, Feng Ma, Piping Jiang, Yumin Wang, Xinjun Zhang, Jichao Chen
Annals of Hematology.2024;[Epub] CrossRef
The effect of ciprofloxacin prophylaxis during haematopoietic cell transplantation on infection episodes, exposure to treatment antimicrobials and antimicrobial resistance: a single-centre retrospective cohort study
Ioannis Baltas, Konstantinos Kavallieros, Giannis Konstantinou, Eirini Koutoumanou, Malick M Gibani, Mark Gilchrist, Frances Davies, Jiri Pavlu
JAC-Antimicrobial Resistance.2023;[Epub] CrossRef
Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL
Akihiro Ohmoto, Shigeo Fuji
Blood Reviews.2021; 46: 100738. CrossRef
Infectious complications during immunochemotherapy of post-transplantation lymphoproliferative disease–can we decrease the risk? Two case reports and review of literature
Aleksandra Gładyś, Sylwia Kozak, Kamil Wdowiak, Mateusz Winder, Jerzy Chudek
World Journal of Clinical Cases.2021; 9(3): 748. CrossRef
Incidence of Pneumocystis jirovecii pneumonia utilizing a polymerase chain reaction‐based diagnosis in patients receiving bendamustine
Mikhaila L. Rice, Jason N. Barreto, Carrie A. Thompson, Kristin C. Mara, Pritish K. Tosh, Andrew H. Limper
Cancer Medicine.2021; 10(15): 5120. CrossRef
Not all bad: Drug-induced interstitial pneumonia in DLBCL patients is potentially fatal but could be linked to better survival
Wen Wei, Yajie Zhu, Jianning Tang, Chuan Xu, Jiman Li, Shuya He, Zhihui Zhang, Ping Wu, Lei Luo, Qin Guo, Fang Li, Yuanrong Ren, Sisi Yu, Renqin Li, Li Li
Leukemia Research.2021; 111: 106688. CrossRef
A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the fina
Sang Eun Yoon, Seok Jin Kim, Dok Hyun Yoon, Youngil Koh, Yeung-Chul Mun, Young Rok Do, Yoon Seok Choi, Deok Hwan Yang, Min Kyoung Kim, Gyeong-Won Lee, Cheolwon Suh, Young Hyeh Ko, Won Seog Kim
Annals of Hematology.2020; 99(6): 1283. CrossRef
Prognostic significance of infectious episodes occurring during first‐line therapy for diffuse large B‐cell lymphoma ‐ A nationwide cohort study
Michael R. Clausen, Sinna P. Ulrichsen, Maja B. Juul, Christian B. Poulsen, Brian Iversen, Per T. Pedersen, Jakob Madsen, Robert S. Pedersen, Pär L. Josefsson, Jette S. Gørløv, Mette Nørgaard, Francesco d'Amore
Hematological Oncology.2020; 38(3): 318. CrossRef
Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494)
Vicki A. Morrison, Edie A. Weller, Thomas M. Habermann, Shuli Li, Richard I. Fisher, Bruce D. Cheson, Bruce A. Peterson
Leukemia & Lymphoma.2017; 58(8): 1814. CrossRef
Pneumocystispneumonia versus rituximab-induced interstitial lung disease in lymphoma patients receiving rituximab-containing chemotherapy
Se Yoon Park, Mi Young Kim, Won Jin Choi, Dok Hyun Yoon, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Cheolwon Suh, Jun Hee Woo, Sung-Han Kim
Medical Mycology.2016; : myw095. CrossRef
Neoplastic fever in patients with bone and soft tissue sarcoma
Tomoki Nakamura, Akihiko Matsumine, Takao Matsubara, Kunihiro Asanuma, Akihiro Sudo
Molecular and Clinical Oncology.2016; 5(5): 631. CrossRef
Can mortality of cancer patients with fever and neutropenia be improved?
Karin A. Thursky, Leon J. Worth
Current Opinion in Infectious Diseases.2015; 28(6): 505. CrossRef

12,843 View
114 Download
13 Web of Science
13 Crossref

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis: Junshik Hong, Seok Jin Kim, Jae-Sook Ahn, Moo Kon Song, Yu Ri Kim, Ho Sup Lee, Ho-Young Yhim, Dok Hyun Yoon, Min Kyoung Kim, Sung Yong Oh, Yong Park, Yeung-Chul Mun, Young Rok Do, Hun-Mo Ryoo, Je-Jung Lee, Jae Hoon Lee, Won Seog Kim, Cheolwon Suh; Cancer Res Treat. 2015;47(2):173-181. Published online October 28, 2014; DOI: https://doi.org/10.4143/crt.2014.055

Abstract PDF PubReader ePub

Purpose
This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI).
Materials and Methods
Patients ≥ 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients’ case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study.
Results
Forty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less than 25% of patients received greater than 80% of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate.
Conclusion
R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.

Citations

Citations to this article as recorded by

Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: A single-arm meta-analysis
Xiaoxuan Lu, Yu Liu, Ruyu Liu, Jiaxin Liu, Xiaojing Yan, Liren Qian
Frontiers in Oncology.2022;[Epub] CrossRef
Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis
Ze‐Long Liu, Pan‐Pan Liu, Xi‐Wen Bi, De‐Xin Lei, Yu Wang, Zhi‐Ming Li, Wen‐Qi Jiang, Yi Xia
Cancer Medicine.2019; 8(3): 874. CrossRef
ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines
Jun Liu, Junshik Hong, Kwang-Sung Ahn, Junhyeok Go, Heejoo Han, Jihyun Park, Dongchan Kim, Hyejoo Park, Youngil Koh, Dong-Yeop Shin, Sung-Soo Yoon
Leukemia & Lymphoma.2019; 60(10): 2532. CrossRef
Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial
Kwai Han Yoo, Hyewon Lee, Cheolwon Suh
International Journal of Hematology.2018; 107(4): 395. CrossRef
Recent advances in treating extra-ocular lymphomas
Lauge Hjorth Mikkelsen, Natacha Storm Würtz, Steffen Heegaard
Expert Review of Ophthalmology.2018; 13(4): 205. CrossRef
The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective
Cheolwon Suh, Byeong-Bae Park, Won Seog Kim
Blood Research.2017; 52(1): 3. CrossRef
Primary lymphomas in the gastrointestinal tract
Jiang Chen Peng, Lu Zhong, Zhi Hua Ran
Journal of Digestive Diseases.2015; 16(4): 169. CrossRef

16,228 View
147 Download
10 Web of Science
7 Crossref

Case Reports

Unusual Manifestation of Intravascular Large B-Cell Lymphoma: Severe Hypercalcemia with Parathyroid Hormone-Related Protein: Jung Min Ha, Eun Kim, Woo Joo Lee, Ji-Won Hwang, Sehyo Yune, Young Hyeh Ko, Joon Young Choi, Seok Jin Kim, Won Seog Kim; Cancer Res Treat. 2014;46(3):307-311. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.307

Abstract PDF PubReader ePub

Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of non-Hodgkin lymphoma. It usually presents with nonspecific symptoms, such as fever, rather than with overt lymphadenopathy. Reports of hypercalcemia, as the initial presentation of IVLBCL, are limited in the literature, despite it being a well-known complication of various solid cancers. We present a 68-year-old male with severe hypercalcemia and increased levels of serum parathyroid hormone-related protein. He was diagnosed with IVLBCL, involving the bone marrow and spleen, and was successfully treated with rituximab-containing chemotherapy. A few previous case reports have shown hypercalcemia in patients with IVLBCL. Much like our case, previous cases with hypercalcemia had advanced diseases, including bone marrow invasion. Although it was an extremely rare manifestation of IVLBCL, we suggest that IVLBCL should be a part of the differential diagnosis in patients with unexplained hypercalcemia. Therefore, an active work-up might be recommended, including positron emission tomography/ computed tomography scan and bone marrow examination, which may be useful for early diagnosis.

Citations

Citations to this article as recorded by

A case of intravascular large B-cell lymphoma complicated by hypercalcaemia
Masahiro Yabe, Takashi Abe, Saori Yamaga, Seiga Ozaki, Katsuhiro Tomiyama, Hideki Hashidate
European Journal of Case Reports in Internal Medicine.2025;[Epub] CrossRef
Case Report: Intravascular Large B-Cell Lymphoma: A Clinicopathologic Study of Four Cases With Review of Additional 331 Cases in the Literature
Yingying Han, Qingjiao Li, Dan Wang, Lushan Peng, Tao Huang, Chunlin Ou, Keda Yang, Junpu Wang
Frontiers in Oncology.2022;[Epub] CrossRef
Imaging Features and Prognostic Value of FDG PET/CT in Patients with Intravascular Large B-Cell Lymphoma
Chae Hong Lim, Sang Eun Yoon, Won Seog Kim, Kyung-Han Lee, Seok Jin Kim
Cancer Management and Research.2021; Volume 13: 7289. CrossRef
Missed diagnosis of lymphoma presenting with humoral hypercalcemia of malignancy due to cessation of oncological workup after negative computed tomography scans
Ellery Altshuler, Mahmoud Aryan, William King, Rolando Otero
BMJ Case Reports.2021; 14(12): e246669. CrossRef
The spectrum of lymphoproliferative disorders in endocrine organs: from histology to molecular genetics
Silvia Uccella, Francesca Magnoli, Cristina Amaglio, Fausto Sessa, Stefano La Rosa
Diagnostic Histopathology.2019; 25(5): 166. CrossRef
Diagnosis of intravascular large B cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20 years
Kosei Matsue, Yoshiaki Abe, Kentaro Narita, Hiroki Kobayashi, Akihiro Kitadate, Masami Takeuchi, Daisuke Miura, Kengo Takeuchi
British Journal of Haematology.2019; 187(3): 328. CrossRef
Klinische und pathologische Charakteristika intravaskulärer Lymphome
L. Abraham, H. Kreipe, P. Raab, K. Hussein
Der Pathologe.2018; 39(3): 242. CrossRef
Primary Bone Marrow B-Cell Lymphoma Undetected by Multiple Imaging Modalities That Initially Presented with Hypercalcemia
Jin Sae Yoo, Juwon Kim, Hyeong Ju Kwon, Jung Soo Lim
Case Reports in Endocrinology.2018; 2018: 1. CrossRef
Klinische und pathologische Charakteristika intravaskulärer Lymphome
Lara Abraham, Hans H. Kreipe, Peter Raab, Kais Hussein
Wiener klinisches Magazin.2018; 21(5): 206. CrossRef

12,711 View
68 Download
7 Web of Science
9 Crossref

Primary Follicular Lymphoma in a Male Breast: A Case Report: Seung Pil Jung, Kang Min Han, Seok Jin Kim, Seok Jin Nam, Jeoung Won Bae, Jeong Eon Lee; Cancer Res Treat. 2014;46(1):104-107. Published online January 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.1.104

Abstract PDF PubReader ePub

Primary breast lymphoma (PBL) is a rare disease, particularly in males. Diffuse large B cell lymphoma is the most common PBL, while follicular lymphoma is less common. Furthermore, primary follicular lymphoma of a male breast is rarely reported. We report a male patient with primary follicular lymphoma of the breast and hepatocellular carcinoma (HCC). A 46-year-old man was diagnosed with liver cirrhosis secondary to chronic hepatitis B infection. Ten years later, he underwent segmentectomy of the liver due to HCC. Another 5 months later, he presented with a painless mass in the right chest wall. The mass was diagnosed as follicular lymphoma of the breast. The stage was IEA and he did not receive adjuvant therapy. Although only a few cases have been reported, lymphoma should be considered as a possible cause of breast mass, even in male patients.

Citations

Citations to this article as recorded by

Clinicopathologic and mutational profiles of primary breast diffuse large B cell lymphoma in a male patient: case report and literature review
Fengbo Huang, Yachao Ruan, Xiaojuan He, Hui Lian, Jinhua Yang
World Journal of Surgical Oncology.2023;[Epub] CrossRef
Primary breast lymphoma in males: Incidence, demographics, prognostic factors, survival, and comparisons with females
Jie Zhang, Binbin Ma, Hong Ji, Rong Guo
Frontiers in Surgery.2022;[Epub] CrossRef
Hematologic Malignancies of the Breast: A Contemporary Series Investigating Incidence, Presentation, Accuracy of Diagnosis on Core Needle Biopsy, and Hormone Receptor Expression
Marie-Christine Guilbert, Jason L Hornick, Sona A Chikarmane, Susan C Lester
Breast Cancer: Basic and Clinical Research.2019;[Epub] CrossRef
Case - lymphoma of breast
Eva Němcová, Andrea Janíková, Jiřina Little, Eva Jandáková, Hana Čučková, Karel Dvořák
Česká radiologie.2015; 69(3): 207. CrossRef

15,822 View
66 Download
5 Web of Science
4 Crossref

Complete Remission in a Patient with Human Herpes Virus-8 Negative Multicentric Castleman Disease Using CHOP Chemotherapy: Hee Yeon Seo, Eui Bae Kim, Jee Won Kim, Bong Kyoung Shin, Seok Jin Kim, Byung Soo Kim; Cancer Res Treat. 2009;41(2):104-107. Published online June 30, 2009; DOI: https://doi.org/10.4143/crt.2009.41.2.104

Abstract PDF PubReader ePub

Multicentric Castleman disease (MCD) is a rare lymphoproliferative disorder. Although MCD pathogenesis is unclear, studies have suggested that human herpesvirus 8 (HHV-8) may be associated with the disorder. Recent reports have identified MCD cases without viral infection. A 43-year-old woman presented to our hospital for fever and myalgia of 6 months' duration. The complete blood count revealed an elevated leukocyte count (15.1×10³/µL) and a decreased hemoglobin level of 10.0 g/dL. The C-reactive protein level was elevated at 276.5 mg/L. Thoracic computed tomography (CT) scans revealed bilateral axillary lymphadenopathy. There was no evidence of HHV-8, human immunodeficiency virus (HIV), or Mycobacterium infection. Histologic evaluation of a lymph node biopsy from the left axilla yielded a diagnosis of MCD. Cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) were administered for a total of 4 cycles. The patient's fever and lymphadenopathy resolved after the course of chemotherapy. She has been in complete remission for 24 months at this writing. As previously reported, this case report suggests that MCD can develop without viral infection. CHOP chemotherapy may be an effective treatment option for newly diagnosed MCD patients.

Citations

Citations to this article as recorded by

A diagnostic and therapeutically challenging presentation of unicentric mesenteric Castleman disease: A case report
Lixin Hua, Zhibin Yin, Ruirui Yang
Experimental and Therapeutic Medicine.2025; 29(4): 1. CrossRef
Autoreactive Antibodies Associated with Castleman Disease Triad
Jacqueline A. Turner, Ali Hakimi, Hannah Lee, Jeffrey T. Schowinsky, Jeffrey M. Sippel, Bradford J. Siegele, Raul M. Torres, William A. Robinson, Necil Kütükçüler
Case Reports in Immunology.2024; 2024: 1. CrossRef
Clinicopathological Profile of Castleman’s Disease in Indian Population: Experience From a Tertiary Care Center
Ashok Singh, Suvendu Purkait, Saumyaranjan Mallick, Prashant Ramteke, Chandan Krushna Das, Ajay Gogia, Maher Chand Sharma, Lalit Kumar
Indian Journal of Hematology and Blood Transfusion.2020; 36(2): 254. CrossRef
Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman’s disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately
Xuan Lan, Zhaoming Li, Mingzhi Zhang
Journal of Cancer Research and Clinical Oncology.2018; 144(7): 1265. CrossRef
Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease
Li Yu, Meifeng Tu, Jorge Cortes, Zijun Y. Xu-Monette, Roberto N. Miranda, Jun Zhang, Robert Z. Orlowski, Sattva Neelapu, Prajwal C. Boddu, Mary A. Akosile, Thomas S. Uldrick, Robert Yarchoan, L. Jeffrey Medeiros, Yong Li, David C. Fajgenbaum, Ken H. Young
Blood.2017; 129(12): 1658. CrossRef
Clinical management of HIV-associated hematologic malignancies
Chia-Ching J. Wang, Lawrence D. Kaplan
Expert Review of Hematology.2016; 9(4): 361. CrossRef
Practical Management of Castleman's Disease
Musa Fares Alzahrani, Mansoor Radwi, Heather A. Leitch
Acta Haematologica.2016; 136(1): 16. CrossRef
Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome
Musa Alzahrani, Mark C. Hull, Christopher Sherlock, Deborah Griswold, Chantal S. Leger, Heather A. Leitch
Leukemia & Lymphoma.2015; 56(5): 1246. CrossRef
An unusual presentation: A case of Multicentric Castleman's disease presenting as bilateral pleural effusions
Priya K. Simoes, Narender Annapureddy, Vaidehi Avadhani, Gangajal Kasnia, Girish N. Nadkarni
HIV & AIDS Review.2015; 14(3): 84. CrossRef
Sustained remission of severe multicentric castleman disease following multiagent chemotherapy and tocilizumab maintenance
Lucie M. Turcotte, Colleen K. Correll, Robyn C. Reed, Christopher L. Moertel
Pediatric Blood & Cancer.2014; 61(4): 737. CrossRef
Diagnosis and Management of Castleman Disease
Jacob D. Soumerai, Aliyah R. Sohani, Jeremy S. Abramson
Cancer Control.2014; 21(4): 266. CrossRef
Multicentric Castleman’s Disease: A Challenging Diagnosis
Györgyi Műzes, Ferenc Sipos, Judit Csomor, Lídia Sréter
Pathology & Oncology Research.2013; 19(3): 345. CrossRef
Clinical Features and Outcomes of Head and Neck Castleman Disease
Yan-Feng Chen, Wei-Dong Zhang, Chuan-Zheng Sun, Dian OuYang, Wen-Kuan Chen, Rong-Zhen Luo, Ming-Wei Wu
Journal of Oral and Maxillofacial Surgery.2012; 70(10): 2466. CrossRef
Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics
Hazem E. El-Osta, Razelle Kurzrock
The Oncologist.2011; 16(4): 497. CrossRef

9,505 View
64 Download
14 Crossref

Hepatitis B Virus Reactivation in a Surface Antigen-negative and Antibody-positive Patient after Rituximab Plus CHOP Chemotherapy: Eui Bae Kim, Dae Sik Kim, Seh Jong Park, Yong Park, Kyoung Ho Rho, Seok Jin Kim; Cancer Res Treat. 2008;40(1):36-38. Published online March 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.1.36

Abstract PDF PubReader ePub

Rituximab is a monoclonal antibody that targets B-lymphocytes, and it is widely used to treat non-Hodgkin's lymphoma. However, its use has been implicated in HBV reactivation that's related with the immunosuppressive effects of rituximab. Although the majority of reactivations occur in hepatitis B carriers, a few cases of reactivation have been reported in HBsAg negative patients. However, reactivation in an HBsAg negative/HBsAb positive patient after rituximab treatment has never been reported in Korea. We present here an HBsAg-negative/HBsAb-positive 66-year-old female who displayed reactivation following rituximab plus CHOP chemotherapy for diffuse large B-cell lymphoma. While she was negative for HBsAg at diagnosis, her viral status was changed at the time of relapse as follows: HBsAg positive, HBsAb negative, HBeAg positive, HBeAb negative and an HBV DNA level of 1165 pg/ml. Our observation suggests that we should monitor for HBV reactivation during rituximab treatment when prior HBV infection or occult infection is suspected, and even in the HBsAg negative/HBsAb positive cases.

Citations

Citations to this article as recorded by

Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens
Rui Lu, Meng Zhang, Zi-Han Liu, Miao Hao, Yan Tian, Mei Li, Feng-Ping Wu, Wen-Jun Wang, Juan-Juan Shi, Xin Zhang, Xiao-Li Jia, Zi-Cheng Jiang, Xue-Mei Li, Guang-Hua Xu, Ya-Ping Li, Shuang-Suo Dang
World Journal of Gastroenterology.2024; 30(44): 4725. CrossRef
Very late-onset hepatitis B reactivation following chemoimmunotherapy
Edward R. Scheffer Cliff, Joe Sasadeusz, Kumar Visvanathan, Andrew Grigg
Leukemia & Lymphoma.2022; 63(4): 991. CrossRef
Development and validation of a nomogram for steroid-resistance prediction in immune thrombocytopenia patients
Jieni Yu, Zhiqiang Xu, Yuanyuan Zhuo, Huahua Wei, Yinhai Ye, Qinhong Xu, Youli Li, Lihong Yu, Weiying Feng, Pan Hong, Kejie Zhang
Hematology.2021; 26(1): 956. CrossRef
Hepatitis B virus reactivation with corticosteroid therapy in patients with adrenal insufficiency
Masako Hatano, Toshihide Mimura, Akira Shimada, Mitsuhiko Noda, Shigehiro Katayama
Endocrinology, Diabetes & Metabolism.2019;[Epub] CrossRef
Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen
Nuria Dominguez, Maria Luisa Manzano, Raquel Muñoz, Ana Martin, Inmaculada Fernandez, Gregorio Castellano
Leukemia & Lymphoma.2015; 56(4): 1160. CrossRef
Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?
Jesse Civan, Hie Won Hann
Expert Opinion on Drug Safety.2015; 14(6): 865. CrossRef
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy
Mauro Viganò, Giampaolo Mangia, Pietro Lampertico
Expert Opinion on Biological Therapy.2014; 14(7): 1019. CrossRef
A Case of Reactivation of Hepatitis B and Fulminant Hepatitis which developed 3 months following Chemotherapy Including Rituximab in a Patient with Lymphoma
Tae Won Lim, Hee Taek Oh, Seung Un Song, Hae Won Lee, Ji Yeon Kim, Seon Ja Park
Kosin Medical Journal.2014; 29(2): 161. CrossRef
Occult Hepatitis B Virus Infection: Transmission and Reactivation
Sang Hee Song, Seong Gyu Hwang
The Korean Journal of Gastroenterology.2013; 62(3): 148. CrossRef
Reactivation of Hepatitis B Virus Following Systemic Chemotherapy for Malignant Lymphoma
Seung Jun Jang, Young Kul Jung, Hae Lim Baek, Hyun Hwa Yoon, Seung Kak Shin, Jun Shik Hong, Jin Ny Park, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Jae Hoon Lee, Ju Hyun Kim
Korean Journal of Medicine.2013; 85(6): 598. CrossRef
Occult Hepatitis B: Clinical Viewpoint and Management
Mehdi Zobeiri
Hepatitis Research and Treatment.2013; 2013: 1. CrossRef
Highly Sensitive Detection of Hepatitis B Virus Surface Antigen by Use of a Semiautomated Immune Complex Transfer Chemiluminescence Enzyme Immunoassay
Kazuhiko Takeda, Mari Maruki, Takahiro Yamagaito, Machiko Muramatsu, Yasuhiro Sakai, Hiroaki Tobimatsu, Hironori Kobayashi, Yoshiteru Mizuno, Yukio Hamaguchi
Journal of Clinical Microbiology.2013; 51(7): 2238. CrossRef
Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy
Shigeru Kusumoto, Yasuhito Tanaka, Ryuzo Ueda, Masashi Mizokami
Journal of Gastroenterology.2011; 46(1): 9. CrossRef
Fulminant Hepatic Failure with Hepatitis B Virus Reactivation after Rituximab Treatment in a Patient with Resolved Hepatitis B
Seong Min Chung, Joo Hyun Sohn, Tae Yeob Kim, Ki Deok Yoo, Yong Woo Ahn, Joong Ho Bae, Yong Cheol Jeon, Jung Hye Choi
The Korean Journal of Gastroenterology.2010; 55(4): 266. CrossRef
Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B
Alessandro Allegra, Giuseppa Penna, Andrea Alonci, Angela Granata, Arianna D’Angelo, Caterina Musolino
Medical Oncology.2010; 27(3): 912. CrossRef

14,675 View
91 Download
15 Crossref

Original Articles

Glucose Transporter-1 Expression in Squamous Cell Carcinoma of the Tongue: Yoon Seok Choi, Seok Jin Kim, Dae Sik Kim, Seh Jong Park, Yong Park, Hye Jin Shin, Kwang-Yoon Jung, Seung-Kuk Baek, Bong Kyung Shin, Jung Woo Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim; Cancer Res Treat. 2007;39(3):109-115. Published online September 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.3.109

Abstract PDF PubReader ePub

Purpose

Tumor cells are known to express hypoxia-related proteins such as glucose transporter-1 (Glut-1). These hypoxia-induced changes may allow tumor cells to survive under sustained hypoxic microenvironments, and the surviving tumor cell under hypoxia may develop a more aggressive phenotype and so result in a poor prognosis.

Materials and Methods

The Glut-1 expression was analyzed by immunohistochemistry, and its association with the prognosis was assessed in 60 patients with squamous cell carcinoma of the tongue.

Results

The Glut-1 expression was diffuse with a membranous pattern, and the median percentage of Glut-1 positive tumor cells was 60% (range: 0.0~90.0%). A high Glut-1 expression (the percentage of positive tumor cells ≥ the median value, 60%) was associated with the location of primary lesion, lymph node metastasis status and disease stage (p<0.05). The expression of Glut-1 was correlated with the Ki-67 expression (r=0.406, p=0.001). Microvessel density, as represented by CD31 staining, was also correlated with the Glut-1 expression although its significance is weak (r=0.267, p=0.039). On the univariate analysis, the group with a high Glut-1 expression showed poorer overall survival than the group with a low Glut-1 expression (p<0.05). However, the Glut-1 expression failed to show any independent prognostic significance on the multivariate analysis.

Conclusion

The expression of Glut-1 may be useful for predicting the prognosis and determining the treatment strategy for the management of squamous cell carcinoma of the tongue.

Citations

Citations to this article as recorded by

Study of expression of GLUT-1 in oral potentially malignant disorders and oral squamous cell carcinoma: An immuno-histochemical analysis
Shylaja K. Attur, Anil Patel, Kailash M. Attur
Journal of Oral and Maxillofacial Pathology.2024; 28(1): 70. CrossRef
Prognostic value of glycolysis markers in head and neck squamous cell carcinoma: a meta-analysis
Yanting Wang, Yuanyuan Li, Laibo Jiang, Xianyue Ren, Bin Cheng, Juan Xia
Aging.2021; 13(5): 7284. CrossRef
The Role of Glucose Transporters in Oral Squamous Cell Carcinoma
Heinrich Botha, Camile S. Farah, Kendrick Koo, Nicola Cirillo, Michael McCullough, Rita Paolini, Antonio Celentano
Biomolecules.2021; 11(8): 1070. CrossRef
Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy
Angara Zambrano, Matías Molt, Elena Uribe, Mónica Salas
International Journal of Molecular Sciences.2019; 20(13): 3374. CrossRef
Can increased metabolic status be a grading tool for oral squamous cell carcinoma? A glucose transporter 1 immunoexpression study
Abikshyeet Panda, Alokenath Bandyopadhyay, Gouse Mohiddin, Malvika Raghuvanshi, SanjayKumar Sahoo, Lipsa Bhuyan
Nigerian Journal of Surgery.2019; 25(2): 203. CrossRef
Plumbagin‐mediating GLUT1 suppresses the growth of human tongue squamous cell carcinoma
S Na, J Zhang, X Zhou, A Tang, D Huang, Q Xu, D Xue, J Qiu
Oral Diseases.2018; 24(6): 920. CrossRef
Expression of GLUT-1 in oral squamous cell carcinoma in tobacco and non-tobacco users
Neha Azad, Malti Kumari Maurya, Meenakshi Kar, Madhu Mati Goel, Ajay Kumar Singh, Mala Sagar, Divya Mehrotra, Vijay Kumar
Journal of Oral Biology and Craniofacial Research.2016; 6(1): 25. CrossRef
Distribution of Hypoxia-Inducible Factor-1α and Glucose Transporter-1 in Human Tongue Cancers
Marcelo Gadelha Vasconcelos, Rodrigo Gadelha Vasconcelos, Denise Hélen Imaculada Pereira de Oliveira, Edilmar de Moura Santos, Leão Pereira Pinto, Éricka Janine Dantas da Silveira, Lélia Maria Guedes Queiroz
Journal of Oral and Maxillofacial Surgery.2015; 73(9): 1753. CrossRef
Expression of glucose transporters in cancers
Leszek Szablewski
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2013; 1835(2): 164. CrossRef
T-Type Ca2+Channels in Normal and Abnormal Brain Functions
Eunji Cheong, Hee-Sup Shin
Physiological Reviews.2013; 93(3): 961. CrossRef
Glucose uptake mediated by glucose transporter 1 is essential for early tooth morphogenesis and size determination of murine molars
Hiroko Ida-Yonemochi, Mitsushiro Nakatomi, Hidemitsu Harada, Hiroki Takata, Otto Baba, Hayato Ohshima
Developmental Biology.2012; 363(1): 52. CrossRef
Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary
Ja Seung Koo, Haeryoung Kim
Tumor Biology.2011; 32(5): 893. CrossRef

10,848 View
57 Download
12 Crossref

Microsatellite Alterations in Serum DNA of Lung Cancer Patients: Sang Cheul Oh, Young Do Yoo, So Young Yoon, Seok Jin Kim, Jae Hong Seo, Kwang Taek Kim, Sang Won Shin, Yo Han Kim, Yeul Hong Kim, Jun Suk Kim; Cancer Res Treat. 2003;35(4):289-293. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.289

Abstract PDF: No abstract available.

4,370 View
19 Download

Editorial

Molecular Markers in Gastric Cancer: Can They Predict Prognosis?: Seok Jin Kim, Yeul Hong Kim; Cancer Res Treat. 2003;35(1):1-2. Published online February 28, 2003; DOI: https://doi.org/10.4143/crt.2003.35.1.1

Abstract PDF

No abstract available.

Citations

Citations to this article as recorded by

Nuclear Factor-κB Activation Correlates with Better Prognosis and Akt Activation in Human Gastric Cancer
Byung Lan Lee, Hye Seung Lee, Jieun Jung, Sung Jin Cho, Hee-Yong Chung, Woo Ho Kim, Young-Woo Jin, Chong Soon Kim, Seon Young Nam
Clinical Cancer Research.2005; 11(7): 2518. CrossRef

3,701 View
20 Download
1 Crossref

First
Prev
Page of 2
Next
Last

Search